**EMORY UNIVERSITY SCHOOL OF MEDICINE**

**STANDARD CURRICULUM VITAE**

Revised 5/28/2022

1. Name: Jeanne Elise Hendrickson, MD

2. Office Address: Emory University Hospital

 1364 E. Clifton Road NE

 Clinical Pathology and Blood Bank, 6th floor

 Atlanta, GA 30322

 Cell: (203) 903-6558

3. E-mail: jeanne.hendrickson@emory.edu

 jeanne.hendrickson@yale.edu

4. Current Titles and Affiliations:

1. Academic Appointment:
	* 1. Primary Appointment:

 Professor (Provisional)

 Department of Pathology and Laboratory Medicine

 Emory University School of Medicine

 7/2022-present

* + 1. Part-Time Appointment:

 Professor

 Department of Laboratory Medicine

 Yale University School of Medicine

 7/2022-present

1. Clinical Appointments:

 Medical Director, Emory University Hospital Hemapheresis

 Service

 Attending Physician, Emory University Hospital Transfusion

 Medicine Service

 Associate Director, Emory Center for Transfusion and Cellular

 Therapies

 Medical Director, Emory St Joseph’s Hospital Infusion Center

 Laboratory

1. Previous Academic and Professional Appointments:

General Pediatrician

Briarcliff Pediatrics

Atlanta, GA

7/2003-6/2004

Staff Physician

Division of Pediatric Hematology/Oncology/BMT

Children’s Healthcare of Atlanta at Scottish Rite

7/2004-6/2005

Assistant Professor

 Division of Pediatric Hematology/Oncology/BMT

Department of Pediatrics

Emory University School of Medicine

7/2008-7/2013

Assistant Professor

 Department of Pathology and Laboratory Medicine

 Center for Transfusion and Cellular Therapies

 Emory University School of Medicine

 7/2008-7/2013

 Assistant Professor

 Department of Laboratory Medicine

 Yale University School of Medicine

 8/2013-6/2014

 Associate Professor

 Department of Laboratory Medicine

 Yale University School of Medicine

 7/2014-6/2019

 Professor

 Department of Laboratory Medicine

 Yale University School of Medicine

 7/2019-6/2022

1. Previous Administrative or Clinical Appointments:

Assistant Medical Director

Children’s Healthcare of Atlanta Blood and Tissue Services

7/2008-6/2010

Associate Medical Director

Children’s Healthcare of Atlanta Blood and Tissue Services

7/2010-7/2013

Associate Medical Director

Yale New Haven Hospital Transfusion Medicine Service

8/2013-6/2022

Associate Medical Director

Yale New Haven Hospital Apheresis Service

8/2013-6/2018

Medical Director

Yale New Haven Hospital Apheresis Service

7/2018-6/2022

Facility Director

Yale New Haven Hospital Apheresis Service

7/2019-6/2022

Vice Chair for Diversity, Equity, and Inclusion

Yale University, Department of Laboratory Medicine

1/2021-6/2022

7. Licenses: GA Medical License, 1999-2013; 2022 to present

 CT Medical License, 2013-2022

8. Specialty Boards: Board Certified, General Pediatrics, 2002, recertified 2012

(expires 2024)

Board Certified, Transfusion Medicine, 2008, recertified in 2018 (in maintenance of certification)

Board Certified, Pediatric Hematology/Oncology, 2009 (expires 2029)

9. Education: University of North Carolina at Chapel Hill

 BS with Highest Distinction

 1992-1994

Medical College of Georgia

 1995-1997

Emory University School of Medicine

 MD with Honors

 1997-1999

10. Postgraduate Training: Emory University Pediatric Residency Program

 Program Director: Susie Buchter, MD

 1999-2002

Pediatric Hematology/Oncology Fellowship

 Emory University

 Aflac Cancer Center and Blood Disorders Service

 Program Director: Thomas Abshire, MD

 2002-2003; 2005-2007

Transfusion Medicine Fellowship

 Emory University

 Center for Transfusion and Cellular Therapies

 Program Director: Christopher Hillyer, MD

 2007-2008

11. Continued Professional Developmental Activities:

Yale University School of Management Executive Education: Medical Leadership Program

2019-2021

12. Military Service: n/a

13. Committee Memberships:

 a. National and International:

* + 1. Member, National Blood Foundation Research and Education Trust, 2011-2015
		2. Member, NIH National Heart, Lung, and Blood Institute (NHLBI) Special Emphasis Panel on Alloimmunization, 2011
		3. Member, Association for the Advancement of Blood & Biotherapies (AABB) Pediatric Transfusion Medicine Subcommittee, 2011-present
		4. Member, American Society of Hematology (ASH) Scientific Review Committee on Transfusion Medicine, 2012-2017
		5. Member, American Society of Hematology Annual Meeting Abstract Review Committee, 2012-present, most years
		6. Member, Domestic Steering Committee, NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS)-III, 2013-2019
		7. Chair, RBC Alloimmunization Group for NHLBI State of the Science in Transfusion Medicine, 2014-2015
		8. Member, National Blood Foundation Board of Trustees, 2015-2020
		9. Co-Chair, Perinatal and Neonatology Section of NHLBI’s Scientific Priorities in Pediatric Transfusion Medicine, 2016
		10. Member, Transfusion, Editor-in-Chief Selection Committee, 2016
		11. Chair, National Blood Foundation Grants Review Committee, 2016-2019
		12. Member, American Society of Hematology Guideline Panel on Sickle Cell Disease-Related Transfusion Support, 2016-2019
		13. Scientific Representative, AABB/National Blood Foundation Grants Finance Working Group, 2017-2018
		14. Member, American Society for Apheresis (ASFA) Sickle Cell Research Committee, 2017-present
		15. Vice-Chair, American Society of Hematology Scientific Committee on Transfusion Medicine, 2017-2018
		16. Chair, American Society of Hematology Scientific Committee on Transfusion Medicine, 2018-2019
		17. Member, Domestic Steering Committee, NHLBI REDS-IV-P, 2019-present
		18. Member, Publications Committee, NHLBI REDS-IV-P, 2019-present
		19. Member, International Working Group on Hemolytic Transfusion Reactions in Patients with Sickle Cell Disease, 2018-2020
		20. Member, International Collaboration for Transfusion Medicine Hemolytic Disease of the Newborn Guideline Development Group, 2018-2020
		21. Member, AABB Nominating Committee, 2018-2020
		22. Member, Department of Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) Working Group, 2020-2021
		23. Member, AABB Public Policy Committee, 2020-present
		24. Member, Alloimmunization Group, NHLBI State of the Science in Transfusion Medicine, 2021-2022
		25. Member, American Society for Apheresis (ASFA), Therapeutic Apheresis Outcomes System Committee, 2022-present
1. Regional:
	* 1. Member, Atlanta Sickle Cell Consortium, 2008-2013
		2. Co-Director, Transfusion Medicine Education Outreach (to Connecticut hospitals), 2013-2022
2. Institutional:
	* 1. Chair, Children’s Healthcare of Atlanta Trauma Massive Transfusion Committee, 2006-2008
		2. Member, Children’s Healthcare of Atlanta Transfusion Committee, 2007-2013
		3. Member, Children’s Healthcare of Atlanta Trauma Committee, 2007-2013
		4. Member, Aflac Cancer and Blood Disorders Center Scientific Leaders Committee, 2009-2013
		5. Member, Aflac Cancer and Blood Disorders Center, Director of Hematology Search Committee, 2009-2012
		6. Member, Scholarly Oversight Committee for Pediatric Hematology Oncology Fellows, 2010-2013
		7. Member, Emory Pediatric Residency Interview Committee, 2010-2013
		8. Member, Children’s Healthcare of Atlanta Pediatric Research Retreat Abstract Review Committee, 2011-2013
		9. Member, Emory Medical Student Research Day Review Committee, 2012-2013
		10. Member, Emory University Research Council Grant Review Committee, 2012-2013
		11. Member, Children’s Healthcare of Atlanta Aflac Quality Guidelines Committee, Chairperson of Transfusion Medicine group, 2012-2013
		12. Member, EPIC Optimization Committee for Transfusion Medicine at Children’s Healthcare of Atlanta, 2012-2013
		13. Chair, Children’s Healthcare of Atlanta Aflac Clinical Quality Improvement Committee in Hematology, 2013
		14. Member (Hematology/Transfusion Medicine representative), Severe Brain Injury Committee, 2013
		15. Member, Yale New Haven Hospital Anticoagulation Reversal Committee, 2013-2014
		16. Co-leader, Yale New Haven Hospital Coagulation Factor Program, 2013-2017
		17. Leader (Transfusion Medicine and Apheresis), Yale New Haven Hospital/Healthcare System EPIC Order Optimization, 2013-2022
		18. Member, Yale University Transfusion and Blood Utilization Committee, 2013-2022
		19. Member (Transfusion Medicine representative), Yale Clinical Pathology Fellowships Clinical Competency Committee, 2013-2022
		20. Member, Yale New Haven Hospital Clinical Redesign to Decrease Blood Wastage, 2015-2016
		21. Member, Yale University Department of Laboratory Medicine Physician Scientist and Clinical Educator Search Committees, 2015-2022
		22. Member, Yale University Scholarly Oversight Committee (Pediatric Hematology/Oncology), 2016-2018; 2021-2022
		23. Member, Yale University Masters in Clinical Research Scholarly Oversight Committee, 2017-2019
		24. Member, Yale University Investigative Medicine Thesis Committee, 2017-2020
		25. Member, Yale University Department of Laboratory Medicine Executive Appointments and Promotions Committee, 2017-2022
		26. Member, Yale University Department of Laboratory Medicine, Clinician Educator Search Committee, 2017-2019
		27. Member, Yale University Department of Laboratory Medicine Executive Finance Committee, 2018-2022
		28. Member, Yale New Haven Hospital Obstetrics/Blood Bank Working Group, 2019-2022
		29. Member, Yale Chimeric Antigen Receptor (CAR) T-cell Steering Committee, 2018-2022
		30. Member, Yale Cellular Therapies Safety and Feasibility Committee, 2018-2022
		31. Member, Yale University Term Appointments and Promotions Committee, 2020-2022
		32. Member, Yale University Scholar Awards Committee, 2020-2021
		33. Member (Laboratory Medicine representative), Dean’s Yale University Interdisciplinary Working Group, 2020-2021
		34. Member (Laboratory Medicine representative), Dean’s Yale University Translational Medicine Working Group, 2020-2021
		35. Member, Yale University COVID Advanced Therapies Group, 2020-2021
		36. Member, Yale University Department of Pediatrics Search Committee for Chair (Hematology/Oncology), 2020-2021
		37. Member, Yale University COVID Clinical Trials Committee, 2020-2022
		38. Founding Member and Chair, Yale Department of Laboratory Medicine Council on Diversity, Equity, and Inclusion, 2021-2022

14. Peer Review Activities:

 a. Grants:

 i. National/International:

1. Member, National Blood Foundation Grants Review Committee, 2007-2016
2. Member, Canadian Blood Services Grant Review Panel, 2014-2019 and 2021-2022
3. Member, Department of Defense Grant Review Panel, 2014-2015 and 2018
4. Ad Hoc member, NHLBI K08/K01 Study Section, 2016
5. Chair, National Blood Foundation Early Career Grant Review Panel, 2016-2019
6. Member, Sanquin Blood Services Grant Review Panel, 2017-2020
7. Ad Hoc Member, NHLBI Transfusion Medicine Study Section, 2017-2020
8. Ad Hoc member, NHLBI K35 Study Section, 2019
9. Ad Hoc member, NIAID Study Section, Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms, 2020
10. Standing Member, NHLBI K08/K01 Study Section, 2020-2022

 ii. Institutional:

1. Member, Emory University Research Council Grant Committee, 2011-2013
2. Member, Yale Cooperative of Excellence in Hematology Pilot Grant Review Committee, 2018-2020
3. Member, Yale Scholar Awards Committee, 2020-2021
4. Manuscripts:

Reviewer, Transfusion, 2006-present

Reviewer, Blood, 2006-present

Reviewer, Journal of Clinical Apheresis, 2008-present

Reviewer, Pediatric Blood and Cancer, 2008-2010

Reviewer, Transfusion Medicine, 2010-present

Reviewer, Journal of Pediatrics, 2010-present

Reviewer, PLOS, 2010-present

Reviewer, Vox Sanguinis, 2010-present

Reviewer, British Journal of Hematology, 2010-present

Reviewer, American Journal of Hematology, 2013-present

Reviewer, European Journal of Immunology, 2013-present

Reviewer, Pediatrics, 2013-present

Reviewer, Blood Advances, 2016-present

Reviewer, Frontiers in Immunology, 2016-present

Reviewer, Transfusion Medicine Reviews, 2016-present

Reviewer, Transfusion and Apheresis Sciences, 2016-present

1. Conference Abstracts:

National/International:

1. Abstract Reviewer, AABB Annual Meeting, most years from 2011-present
2. Abstract Reviewer, American Society of Hematology (ASH), most years from 2012-present
3. Abstract Reviewer, Academy of Clinical Laboratory Physicians and Scientists (ACLPS) Annual Meeting, 2018-present

15. Consultantships/Advisory Boards: Expert Witness for Legal Case, 2021

16. Editorships and Editorial Boards:

 i. Editorial Board, Transfusion, 2011-present

ii. Guest Editor, Hematology Clinics of North America, Transfusion Medicine issue, 2015

iii. Editorial Board, Blood, 2018-present

iv. Associate Editor, Blood, 2021-2022

17. Honors and Awards: University of North Carolina (UNC) Freshman Woman’s

Scholarship, 1993

CRC Press UNC Most Outstanding Freshman Chemistry Award, 1993

UNC Pharmacology Summer Research Fellowship, 1994

Phi Beta Kappa, 1994

Medical College of GA Dean’s Student Research Fellow Award, 1996

Medical College of GA Excellence in Scholarship, 1997

Medical College of GA USMLE Honors, 1997

Janet Glasgow Memorial Award (Top 5% Female Medical Graduates), 1999

Emory Pediatric Continuity Clinic Resident Award, 2000

National Blood Foundation Scholarship Award, 2005

American Society of Hematology Annual Meeting Travel Award, 2005

NIH National Research Science Award T-32 Training Grant, 2005-2007

Emory University Pediatric Fellow Research Competition, 2nd place, 2006

American Society of Hematology Annual Meeting Travel Award, 2006

Baxter Transfusion Medicine Scholarship, 2006

Emory University Pediatric Fellow Research Competition Winner, 2007

American Society of Hematology Fellow Scholar Award, 2007

Emory University Pathology Academic Scholar Award, 2008

Emory University President’s Council on the Status of Women: Award for Relational Mentoring, 2012

Emory Pediatric Hematology/Oncology Fellows Teaching Award, 2013

National Blood Foundation Hall of Fame, 2016

AABB Presidential Award, 2017

Yale University Pathology Resident Teacher of the Year Award, 2018

National Blood Foundation/AABB Professional Engagement Program Shining Star Award, 2019

Wiley “Best Paper” Research Innovation in Scientific Excellence Award, Transfusion, 2020

Ellis Benson Award, Academy of Clinical Laboratory Physicians and Scientists, 2020

1. Society Memberships: American Academy of Pediatrics, 1999-2010

American Society of Hematology, 2002-present

Association for the Advancement of Blood and Biotherapies

(AABB), 2005-present

American Society of Pediatric Hematology/Oncology, 2005-2013

American Society of Bone Marrow Transplantation, 2006-2010

American Society for Clinical Pathology, 2010-2015

Academy of Clinical Laboratory Physicians and Scientists, 2013-present

1. Organization of Conferences:
	* + - * National and International

Administrative Positions:

Member, Scientific Committee on Transfusion Medicine (organizing Scientific and Education programs), American Society of Hematology Annual Meeting, 2012-2017

Vice Chair, Scientific Committee on Transfusion Medicine (organizing Scientific and Education programs), American Society of Hematology Annual Meeting, 2017

Chair, Scientific Committee on Transfusion Medicine (organizing Scientific and Education programs), American Society of Hematology Annual Meeting, 2018

Sessions as Chair:

Chair, National Blood Foundation Grants Recipient Symposium, Association for the Advancement of Blood and Biotherapies, 2016

Chair, National Blood Foundation Grants Recipient Symposium, Association for the Advancement of Blood and Biotherapies, 2017

Chair, Scientific Program for Transfusion Medicine, American Society of Hematology Annual Meeting, 2018

Chair, National Blood Foundation Grants Recipient Symposium, Association for the Advancement of Blood and Biotherapies, 2018

1. Clinical Service Contributions:
	* + - * I served as the Medical Director of the Apheresis Service at Yale from July 2018 through June 2022 and as an Attending Physician from 2013-2022. As part of my Apheresis clinical service, I provided medical oversight for inpatients and outpatients who were undergoing RBC exchange transfusions, therapeutic apheresis procedures, and stem cell collections (autologous and allogeneic); I also oversaw the apheresis portions of more than 10 clinical and research trials involving mononuclear cell collection. Under my supervision, we saw at least 30 patients per week in our Apheresis Unit for clinical care and additional patients undergoing collections for research. During my time as Medical Director, I optimized mobilization standard operative procedures for cellular therapy collections, generated standard operating procedures for tandem procedures, incorporated an after-hours nursing apheresis service to increase Yale RN retention, and optimized/audited physician activities. Under my leadership, our service grew from 0 mononuclear cell collections in 2017 to 46 in 2021; in 2021, other volumes included 675 plasma exchange, 182 red blood cell exchange, 193 autologous stem cell collections, and 27 allogeneic stem cell collections. I also supervised medical students, residents, and fellows on the Apheresis Service. As the Medical Director, I was responsible for apheresis-relevant standard operating procedures and for being inspection ready for organizations such as Foundation for the Accreditation of Cellular Therapy (FACT) and AABB (Association for the Advancement of Blood & Biotherapies).
				* I served as the Associate Medical Director of the Transfusion Medicine Service at Yale from July 2013 through June 2022. In combination with the Medical Director (Chris Tormey) and other faculty, I provided medical supervision of the Blood Bank. I investigated potential transfusion reactions, new RBC alloantibody identifications, and assisted with difficult crossmatches. I supervised residents and fellows in this regard, and we investigated approximately 50 such cases per week (from 2020-2022, I billed for 134 transfusion reaction notes and for 679 difficult crossmatch notes). In combination with other physicians, I met quarterly with members of the hospital staff in a “Transfusion Committee” format, to review transfusion practices. Over the course of my 9 years in this position, I led or participated in multiple quality improvement projects including optimization of transfusion care for patients with sickle cell disease through red blood cell phenotyping/genotyping, optimization of intrauterine transfusion practices, optimization of neonatal red blood exchange through efficient product preparation, optimization of blood product orders and indications in the electronic medical record system, and transfer of coagulation factors from the blood bank to the pharmacy with quality metric tracking.
				* From 2008 to 2013, I served as the Assistant and then Associate Medical Director of the Children’s Healthcare of Atlanta Transfusion Service, as well as an Attending Physician in the Aflac Cancer and Blood Disorders Services. In these roles, I helped to oversee transfusion medicine activities at the Egleston and Scottish Rite campuses and I cared for inpatients and outpatients with hematologic conditions (including sickle cell disease).
2. Community Outreach:

2002-2004, Pediatrician Representative, Georgia Breastfeeding Advisory Council

2002-2013, Pediatric Hematology Oncology Camp Sunshine Volunteer, 2 weekend/year

2004-2013, Pediatric Sickle Cell Disease Camp Volunteer

2008-2013, Atlanta Sickle Cell Education Day Planning Member and Volunteer

2008-2013, Atlanta Sickle Cell Disease Consortium

2012, Girls Softball Coach, Murphy Candler Girls Softball Association

2018-2022, Parent Volunteer, First Congregational Church of Guilford, Pilgrim Fellowship Community Outreach Program

1. Formal Teaching:
2. Medical Student Teaching:
	* 1. Emory School of Medicine, Foundations of Medicine Hematology Module, Introduction to Transfusion Medicine (2008-2012, 2 hours)
		2. Emory School of Medicine, Hematopathology/Blood Group Morphology Group Leader (2008-2012, 8 hours)
		3. Emory MD/PhD Clinical Research Conference (MDPH 799R/IBS 799R), Mentor/Lecturer (2011, 20 hours)
		4. Yale School of Medicine, M2 Laboratory Medicine Case Studies (2013-2018, 2 hours).
		5. Yale School of Medicine, M4 Capstone Course Lecturer, Introduction to Transfusion Medicine (2017-2022, 2 hours)
3. Graduate Programs:
	1. Residency Programs:
		1. Emory Pathology Residency Program, 2008-2013, Faculty (formal lectures 20 hours). Oversaw clinical care of transfusion medicine and apheresis patients; lectured on transfusion medicine and pediatric transfusion medicine; helped to plan and write chapters/edit a book dedicated to the education of pathology residents and transfusion medicine fellows; helped to develop the educational curriculum for the transfusion medicine rotation based on this textbook (including web-based learning and quizzes).
		2. Emory Pediatric Residency Program, 2008-2013, Faculty (formal lectures 4 hours). Oversaw residents that were interested in classical hematology or transfusion medicine; lectured on massive transfusion, sickle cell disease, and other topics.
		3. Yale Pathology Residency Program, 2013-2022, Faculty (formal lectures 10 hours). Oversaw clinical care of transfusion medicine and apheresis; lectured on multiple topics including sickle cell disease, apheresis, transfusion reactions, hemolytic disease of the fetus and newborn, pediatric transfusion medicine. Participated in clinical pathology weekly conferences and monthly journal club.
		4. Yale Pediatric Residency Program, 2013-2022, Faculty (formal lectures 2 hours). Taught transfusion medicine and transfusion reactions.
		5. Danbury Pathology Residency Program, 2013-2022, Course Co-Director (formal lectures 5 hours). Oversaw an outreach program to teach Transfusion Medicine/Apheresis to a residency program at a community hospital in Western CT without a significant transfusion medicine faculty presence. This outreach included 8-12 lectures/year by multiple faculty, in addition to supervision of residents as they rotated through the Yale Transfusion Medicine service.
		6. Yale Affiliated Lecture Series to Surrounding Residency Programs, Lecturer, 2013-2022 (formal lectures 5 hours). Participated in this Lecture Series by providing introductory transfusion medicine and coagulation lectures to Internal Medicine Residency Programs throughout the state of Connecticut.
	2. Fellowship Programs:
		1. Emory Transfusion Medicine Fellowship Program, 2008-2013, Faculty (formal lectures 10 hours). Oversaw clinical care, particularly in the pediatric transfusion medicine realm. Lectured on multiple topics including transfusion reactions, sickle cell disease, and pediatric transfusion medicine. Participated in Clinical Pathology noon conference presentations, working with fellows and residents.
		2. Emory Pediatric Hematology/Oncology Fellowship Program, 2008-2013, Faculty (formal lectures 15 hours). Taught pediatric transfusion medicine and apheresis/cellular therapy to fellows, including co-leadership of an intensive 3-day course (“Introduction to Transfusion Medicine”)
		3. Yale Transfusion Medicine Fellowship Program, 2013-2022, Faculty (formal lectures 10 hours). Oversaw clinical care on transfusion medicine and apheresis rotations for 3 fellows annually, lectured on multiple topics as described in the Yale Residency section. Organized and led a weekly fellow-specific journal club/interesting case conference/board review (52 hours).
		4. Yale Pediatric Hematology/Oncology Fellowship Program, 2013-2022, Faculty (formal lectures 2 hours). Taught pediatric transfusion medicine and apheresis/cellular therapy to fellows, including a board-review focused lecture.
		5. Yale Neonatology Fellowship Program, 2013-2020, Lecturer (formal lectures 2 hours). Taught about hemolytic disease of the fetus and newborn as well as neonatology alloimmune thrombocytopenia.
		6. Yale Pulmonology Fellowship Program, Lecturer, 2013-2022 (formal lecture 1 hour). Taught about transfusion reactions, with a focus on pulmonary reactions.
4. Other Programs
	* 1. Emory PA Student Program, 2008-2013. Gave lectures in hematology, transfusion medicine, hemoglobinopathies (4 hours).
		2. Children’s Healthcare of Atlanta Hematology/Oncology Nursing Staff, 2008-2013. Gave lectures in transfusion medicine, autoimmune hemolytic anemia, sickle cell disease (4 hours).
		3. Children’s Healthcare of Atlanta Laboratory Staff, 2008-2013. Gave lectures on massive transfusion protocols and sickle cell disease/red blood cell alloimmunization (2 hours).
		4. Children’s Healthcare of Atlanta Trauma Nurses, 2008-2013. Gave lectures on transfusion medicine and massive transfusion protocols (4 hours).
		5. Quinnipiac PA Student Program, 2013-2015. Gave lectures on transfusion medicine (2 hours).
		6. Yale New Haven Hospital Blood Bank Staff, 2013-2022. Gave information sessions on red blood cell alloimmunization (1 hour).
		7. Yale New Haven Hospital Apheresis Nursing Staff, 2013-2022. Gave information sessions on topics such as pediatric apheresis, autologous stem cell collection goals, and mononuclear cell collections for CAR T-cell production (6 hours).
5. Supervisory Teaching:
6. PhD Students Directly Supervised:
	* 1. Seema R. Patel, PhD; helped to mentor her along with her primary mentor, Jim Zimring, 2006-2010, Current Position: Staff Scientist, Children’s Healthcare of Atlanta
		2. Christopher R. Gilson, PhD; helped to mentor him along with his primary mentor, Jim Ziming, 2007-2008, Current Position: Scientist in Pharmaceutical Industry, Hartford, CT
		3. Krystalyn E. Hudson, PhD; helped to mentor her along with her primary mentor, Jim Zimring, 2007-2011, Current Position: Assistant Professor, Columbia University
		4. Justine Liepkalns, PhD; helped to mentor her along with her primary mentor, Jim Zimring, 2008-2012, Current Position: Faculty, University of Washington
		5. Kathryn R. Girard-Pierce, PhD; served as her PhD Advisor after Jim Zimring moved from Emory; 2009-2013, Thesis Title: “Investigation into the Development and Consequences of RBC Alloimmunization,” Current Position: Scientist in Pharmaceutical Industry.
		6. Susanna Curtis, MD, PhD; served as one of her PhD advisors, 2018-2020, Thesis Title: “Cannabinoids for the Reduction of Pain and Inflammation in Sickle Cell Disease,” Current Position: Assistant Professor, Albert Einstein College of Medicine
7. Postdoctoral Fellows Directly Supervised:
	* 1. Jennifer Andrews, MD, 2008-2011; Current Position: Associate Professor, Vanderbilt
		2. Thomas Cash, MD, MSc, 2009-2013; Current Position: Associate Professor, Emory/Children’s Healthcare of Atlanta
		3. Joanna Newton, MD, MSc, 2011-2013; Current Position: Assistant Professor, Emory/Children’s Healthcare of Atlanta
		4. R. Shep Nickel, MD, 2011-2015; Current Position: Assistant Professor, Children’s National
		5. H. Cliff Sullivan, MD, 2011-2013; Current Position: Assistant Professor, Emory
		6. Sean Stowell, MD, PhD, 2011-2013; Current Position: Associate Professor, Harvard
		7. Alex Ryder, MD, PhD, 2013-2015; Current Position: Industry
		8. Prabitha Natarajan, PhD, 2014-2017; Current Position: Pharmaceutical Industry
		9. Eric Gehrie, MD, 2014-2016; Current Position: Medical Director at American Red Cross
		10. David Gibb, MD, PhD, 2015-2017; 2018-2022 as K08 Mentor. Position: Assistant Professor of Pathology and Laboratory Medicine, Cedars Sinai
		11. Caleb Cheng, MD, MBA, 2016-2017; Current Position: Pathologist at Caris Life Sciences
		12. Burak Bahar, MD, 2016-2017; Current Position: Director of Informatics, Children’s National
		13. D. Jeremy Madrid, MD, 2016-2018; Current Position: Assistant Professor, Dartmouth
		14. Susanna Curtis, MD, PhD, 2017-2020; Assistant Professor, Albert Einstein College of Medicine
		15. Raisa Balbuena-Merle, MD, 2017-2019; Current Position: Assistant Professor, Yale University
		16. Ian Baine, MD, PhD, 2018-2019; Current Position: Assistant Professor, Icahn School of Medicine at Mount Sinai
		17. Vicente Escamilla-Rivera, PhD, 2019; Current Position: Post-Doctoral Fellow, U. of Arizona
		18. Gaurav Gupta, MD, PhD. 2019-2020; Current Position: Assistant Professor, Memorial Sloan Kettering
		19. Nataliya Sostin, MD, 2019-2020; Current Position: Assistant Professor, Yale
		20. Edward Lee, MD, PhD, 2021-2022; Current Position: Clinical Pathology Resident in Research Years
8. Thesis Committees:
	* 1. Kathryn Girard Pierce (defended her PhD in 2013, thesis title “Investigation into the Development and Consequences of RBC Alloimmunization”)
		2. Raisa Balbuena Merle (defended her MHS in 2019, thesis title: “Immunohematology Variables and Disease Aspects that Impact Red Blood Cell Alloimmunization”)
		3. Susanna Curtis (defended her PhD in 2020, thesis title: “Cannabinoids for the Reduction of Pain and Inflammation in Sickle Cell Disease”)

1. Other:
	* 1. Participated in Yale Pathways to Cure Summer Program, mentored undergraduate Daniel Beitler (2016)
		2. Mentored physician scientist visiting scholar from China, Zimin Shi (2018)
		3. Participated in Yale NIDDK R35 Summer Program, mentored undergraduate James Forsmo (2019)
		4. Coordinated Yale Cooperative Center of Excellence in Hematology Summer Scholars Program, June-July 2021, 60 hours. 12 undergraduate students were placed in labs, including Aaron Jackson in my lab. Lectures were coordinated and given on transfusion medicine, apheresis, hemoglobinopathies, RNA sequencing, iron metabolism, diversity/equity/inclusion, sickle cell disease, host/viral interactions, blood smears.
2. Lectureships, Seminar Invitations, and Visiting Professorships:
3. National and International:
	1. “RBC Alloimmunization: Of Mice, Men, and Women,” Puget Sound Blood Center Grand Rounds, April 2011
	2. “RBC Alloimmunization: Of Mice, Men, and Women,” New York Blood Center Research Conference, April 2011
	3. “Immune Responses to Transfused RBCs: Translational Considerations,” Seattle Children’s Hospital Pediatric Hematology/Oncology Grand Rounds, June 2011
	4. “RBC Alloimmunization: Bench to Bedside and Back,” Establissement Francais du Sang (EFS), Cretil, France, July 2011:
	5. “RBC Alloimmunization: From Bedside to Bench,” Yale University Department of Laboratory Medicine Seminar, August 2012
	6. “Sickle Cell Disease and Transfusion Support,” Association for the Advancement of Blood and Biotherapies Audio Seminar, October 2012
	7. “Factors That Regulate RBC Alloimmunization: Lessons Learned From Murine Models,” Association for the Advancement of Blood and Biotherapies Audio Seminar, July 2013
	8. “Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models,” Keenan Research Centre Li Ka Shing Knowledge Institute and St. Michael’s Hospital Transfusion Medicine Grand Rounds Invited Speaker, Toronto Canada, May 2014
	9. “Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models,” Harvard/Boston Children’s Grand Rounds, March 2014
	10. “The Effect of Whole Blood Mirasol Treatment on RBC Alloimmunization (in a murine model),” Terumo Seminar, October 2014
	11. “Induction and Prevention of RBC Alloimmunization,” Blood Center of Wisconsin/Blood Research Institute Grand Rounds, March 2017
	12. “Responsiveness and Non-Responsiveness to RBC Antigens,” Penn/CHOP Blood Center Seminar Series, May 2017
	13. “Immunoprophylaxis against RBC Antigens: Successes and Failures,” Columbia University 50th Anniversary Symposium of the Licensure of RhIg, September 2018
	14. “RBC Alloimmunization: The Scope of the Clinical Problem in the United States,” NIH Red Blood Cell Genotyping Symposium, September 2018
	15. “RBC Alloimmunization and Delayed Hemolytic Transfusion Reactions,” First Annual International Working Group on Delayed Hemolytic Reactions in Sickle Cell Disease, Etablissement Francais du Sang (EFS), Cretil, France, December 2018
	16. “Recipient Factors Influencing RBC Alloimmunization,” International Society of Blood Transfusion Annual Meeting, Basel Switzerland, July 2019
	17. “Therapeutic Plasma Exchange Plus Targeted Therapies for Neuro-Immune Diseases,” Pathology and Laboratory Medicine Grand Rounds at Dartmouth University, September 2019
	18. “Red Blood Cell Alloimmunization in Transfusion Recipients and Blood Donors: Lessons Learned from REDS-III (Recipient Epidemiology and Donor Study-III) and Beyond,” University of Toronto Grand Rounds, May 2020
	19. “Red Blood Cell Alloimmunization: All the Time or Almost Never?,” Academy of Clinical Laboratory Physicians and Scientists Annual Meeting Ellis Benson Award Lecture, June 2020
	20. “What Really Causes Red Blood Cell Alloimmunization?,” University of Rochester Grand Rounds, October 2020
	21. “RBC Alloantibodies: Danger signals, Complement and Evanescence, Oh My!,” Penn/CHOP Blood Center for Patient Care and Discovery Seminar Series, November 2021
	22. “Induction and Consequences of RBC Alloimmunization, with a Focus on Sickle Cell Disease,” Sloan Kettering Grand Rounds, January 2022
	23. “Induction and Consequences of RBC Alloimmunization, with a Focus on Sickle Cell Disease,” Harvard Hematology Grand Rounds, February 2022
	24. “How Can We Prevent Dangers of RBC Alloantibodies?,” University of British Columbia, 11th Annual Norman Bethune Symposium, April 2022
	25. “A National Antibody Registry Proposal,” Margot Kruskall Lectureship Symposium (Brigham and Women’s Hospital), Delayed Hemolytic Transfusion Reactions: Diagnosis, Treatment, and Future Directions, May 2022
	26. “RBC Alloantibody Evanescence and the Patient Safety Initiative to Exchange RBC Antibody Data US-Wide,” South Central Association of Blood Banks, Advanced Immunohematology and Molecular Symposium, May 2022

1. Regional:
	1. “Transfusion Medicine Update (Kcentra, Novel Oral Anticoagulants),” Greenwich Hospital Grand Rounds, CT, 2013
	2. “Coagulation Concentrates,” Greenwich Hospital Invited Lecture Series, CT, 2013
	3. “Transfusion Reactions,” Greenwich Hospital Invited Lecture Series, CT, 2013
	4. “Transfusion Reactions,” Yale Affiliate Lectures and Grand Rounds, Danbury Hospital, CT, 2014
	5. “Transfusion Reactions,” Yale Affiliate Lectures and Grand Rounds, St. Mary’s Hospital, CT, 2015
	6. “Transfusion Indications and Reactions,” St. Mary’s Hospital Grand Rounds, CT, Internal Medicine, 2016
	7. “Transfusion Indications,” Yale Affiliate Invited Lecture Series and Grand Grounds, Danbury Hospital, CT, 2016
	8. “Transfusion Indications,” Yale Affiliate Invited Lecture Series, Norwark Hospital, CT, Internal Medicine, 2016
	9. “Transfusion Support for Patients with Sickle Cell Disease,” Yale Affiliate Lecture Series, Danbury Hospital, CT, Internal Medicine, 2017
	10. “Transfusion Reactions,” Yale Affiliate Invited Lecture Series for Trainees, Greenwich Hospital, CT, 2017
	11. “Transfusion Reactions,” Yale Affiliate Grand Rounds, Bridgeport Hospital, CT, 2018

1. Institutional:
	1. “Inflammation and Alloimmunization,” Aflac Cancer Center and Blood Disorders Service Seminar, November 2007
	2. “General Clinical Transfusion Practices,” Introduction for Aflac Established Nurses, August 2010
	3. “Advanced Glycation End Products on Stored RBCs,” Center for Transfusion and Cellular Therapies, September 2010
	4. “The Increased Immunogenicity of Stored Murine RBCs,” Aflac Cancer Center and Blood Disorders Service Seminar, December 2010
	5. “RBC Alloimmunization and Sickle Cell Disease,” Aflac Cancer Center and Blood Disorders Service Seminar, January 2011
	6. “RBC Alloimmunization and Sickle Cell Disease,” Emory Center for Transfusion and Cellular Therapy Research in Progress, February 2011
	7. “Trauma Associated Coagulopathy and Massive Transfusion,” Children’s Healthcare of Atlanta Hematology/Oncology Conference, February 2011
	8. “Children’s Healthcare of Atlanta’s Trauma Massive Transfusion Protocol: Implementation and Outcome,” Emory Pediatric Surgery Trauma Grand Rounds, October 2011
	9. “Coagulopathy and Transfusion Support of Pediatric Trauma Victims,” Children’s Healthcare of Atlanta Trauma Education Day, January 2012
	10. “A Novel Model of Pregnancy and Transfusion Associated Anti-KEL RBC Alloimmunization,” Emory Center for Transfusion and Cellular Therapies Research Meeting, February 2012
	11. “Trauma Associated Coagulopathy” and “Massive Transfusion in a Pediatric Setting,” Children’s Healthcare of Atlanta Nurse Trauma Specialist Course, June 2012
	12. “RBC Alloimmunization and the Spleen: Of Inflammation, Adjuvants, and Anamnestic Responses,” Emory Center for Transfusion and Cellular Therapies Research Meeting, August 2012
	13. “Pregnancy and Transfusion Induced Anti-KEL RBC Alloimmunization,” Alfac Cancer Center and Blood Disorders Research Talk, January 2013
	14. “KEL RBC Alloimmunization: Bedside and Bench Considerations,” Aflac Cancer Center and Blood Disorders Research Talk, June 2013
	15. “RBC Alloimmunization: Transfusion and Pregnancy Considerations,” Yale Department of Pediatrics Research in Progress, October 2014
	16. “KEL Immunoprophylaxis,” Yale Department of Laboratory Medicine Faculty Research in Progress, March 2015
	17. “Bedside to Bench Studies of KEL RBC Alloimmunization: Transfusion and Pregnancy Considerations,” Yale Human Translational Immunology Seminar, March 2015
	18. “Transfusion Medicine, Benefits and Hazards,” Yale Pathway to a Cure High School Summer Program, June 2016, June 2017, June 2018
	19. “Immunoprophylaxis against RBC Antigens: Successes and Failures,” Yale Department of Laboratory Medicine Retreat, October 2017
	20. “An Investigation of RBC Antigen Modulation,” Yale Cooperative Center for Excellence in Hematology Seminar Series, November 2018
	21. “Recipient Factors Influencing Red Blood Cell Alloimmunization,” Yale Human Translational Immunology Seminar, March 2019
2. Invitations to National/International, Regional, and Institutional Conferences:
3. National and International:
	1. “Transfusion Thresholds for Children with Sickle Cell Disease,” Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting Educational Session, October 2010
	2. “RBC Alloimmunization: Of Mice, Men, and Women,” European Society of Hematology Annual Meeting, London, England, July 2011
	3. “Transfusion Support for Children with Sickle Cell Disease Undergoing Myeloablative Matched Sibling Transplant,” AABB Annual Meeting Educational Session, October 2011
	4. “RBC Alloimmunization: Lessons Learned from Murine Models,” AABB Annual Meeting Educational Session, October 2011
	5. “Interactive Session: Transfusion Medicine for Physicians,” AABB Annual Meeting Educational Session, October 2011
	6. “Development and Implementation of a Pediatric Massive Transfusion Protocol,” International Society for Blood Transfusion Education Session, Cancun, Mexico July 2012
	7. “RBC Alloimmunization and Hemolytic Disease of the Fetus and Newborn: New Approaches Using Animal Models,” American Society of Hematology Annual Meeting Scientific Session, December 2013
	8. “Antibody Detection Methodologies: Gelling, Sticking, and Clumping,” AABB Annual Meeting, October 2014
	9. “Speed Dating” in Blood Banking & Apheresis: Hot Topics for Diagnosis and Therapeutic Interventions,” American Society for Clinical Pathology Annual Meeting, September 2014
	10. “RBC Alloimmunization During Pregnancy: a First Look at Mechanisms, Consequences, and Therapeutics,” Society for Reproductive Investigation, March 2015
	11. “Antibody Mediated Modulation of the KEL Glycoprotein on Murine RBCs,” Red Blood Cell Club, October 2015
	12. “Speed Dating in Blood Banking, Apheresis, and Coagulation: A Family Affair” (Topic: Neonatal Alloimmune Thrombocytopenia), American Society for Clinical Pathology Annual Meeting, October 2015
	13. “Transfusion Support Considerations for Patients with Sickle Cell Disease” and “Delayed Hematologic Transfusion Reactions,” American Society for Clinical Pathology (ASCP) Annual Meeting, September 2016
	14. “Understanding RBC Alloimmunization Triggers,” Joint American Society of Hematology/AABB, ASH Annual Meeting, December 2016
	15. “Who are RBC Alloantibody Responders and What Can We Do For Them?,” AABB, October 2016
	16. “RBC Alloimmunization: Of Mice, Men, and Women,” Academy of Clinical Laboratory Physicians and Scientists Invited Speaker at Annual Meeting, June 2017
	17. “RBC Alloimmunization: Induction of Immunity and Potential Mitigation Strategies,” International Society for Blood Transfusion Annual Meeting, Copenhagan, June 2017
	18. “Clinical Challenges Associated with Transfusing Patients with Multiple RBC Alloantibodies: What Can we do for Them?, “ AABB Annual Meeting, October 2017
	19. Examining the Evidence from Human Studies and Animal Models,”
	20. “50 Years Later: The Current Status of the Epidemiology, Pathophysiology, and Treatment of Rh Disease,” AABB Annual Meeting, October 2018
	21. “Current and Emerging Targeted Therapies for Neuro-Immune Diseases,” American Society for Apheresis Annual Meeting Invited Speaker, May 2019
	22. “COVID-19 and the Patient: How the Pandemic is Escalating Health Disparities,” American Society of Clinical Pathology Special Seminar, July 2020
	23. “Red Blood Cell Alloimmunization: Danger Signals Lead to Dangerous Outcomes,” AABB Annual Meeting Education Session, October 2020
	24. “Platelet Potpourri: A Transfusion Medicine Perspective,” Hemostasis and Thrombosis Research Society Annual Meeting, March 2021
	25. “Building the Pediatric Transfusion Medicine Evidence Base: New Insights from Database Research,” AABB Annual Meeting Invited Session, October 2021
4. Regional:
	1. “Inflammation and RBC Alloimmunization,” Southeast AABB, March 2008
	2. “Massive Transfusion in the Pediatric Setting,” Southeast AABB, March 2009
	3. “Transfusion Support for Patients with Hemoglobinopathies,” Southeast AABB, March 2010
	4. “Massive Transfusion Protocol Development and Implementation: The Children’s Healthcare of Atlanta Experience,” Southeast AABB, March 2011
	5. “Transplantation for Sickle Cell Disease: Past, Present, and Future Considerations,” Southeast AABB, March 2012
	6. “Bedside to Bench Studies of KEL: Transfusion and Pregnancy Considerations,” Southeast AABB, March 2013
5. Abstract Presentations at National/International, Regional, and Institutional Conferences:
6. National and International:
	1. \*Hendrickson JE, Record ES, Winters TN, Files B. A Comprehensive Pediatric Pulmonary Sickle Cell Clinic: Attempting to Reduce Lung Complications. (Oral) Presentation at the Sickle Cell Disease Association of America Annual Meeting, 2005.
	2. \*Hendrickson JE, Winters TN, File B. Progression of Cerebrovascular Disease on Hydroxyurea: A Case Report. (Poster) Presentation at the 28th Annual Sickle Cell Disease Program, 2005.
	3. \*Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC. Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells. (Poster) Presentation at the 47th American Society of Hematology Annual Meeting, 2005. Blood 2005, 106 (11): 1887.
	4. \*Hendrickson JE, Roback JD, Hillyer CD, Zimring JC. Mechanisms by Which Recipient Inflammation Enhances Alloimmunization to Red Blood Cell Antigens. (Oral) Presentation at the AABB Annual Meeting, 2006. Transfusion 2006, 46 (Supplement): S48-030J
	5. \*Hendrickson JE, Chadwick TE, Zimring JC. Transfusion in the Absence of Inflammation Induces Tolerance to Red Blood Cell Antigens. (Oral) Presentation at the AABB Annual Meeting, 2006. Transfusion 2006, 46 (Supplement): S50-030J.
	6. \*Hendrickson JE, Josephson CD, Chadwick TE, Zimring JC. Lack of Alloantibody Response in Juvenile Mice Following Transfusion: Non-Immunogenic or Tolerogenic Response? (Poster) Presentation at the 48th American Society of Hematology Annual Meeting, 2006. Blood 2006, 108(11): 955.
	7. \*Hendrickson JE, Roback, JD, Hillyer CD, Zimring JC. Recipient Inflammation that Increases Alloimmunization Also Enhances Consumption of Transfused Red Blood Cells by Dendritic Cells. (Oral) Presentation at the 48th American Society of Hematology Annual Meeting, 2006. Blood 2006, 108 (11): 23.
	8. \*Hendrickson JE, Clements LN, Rosenberg ES, Brown RC. Intra-patient Variability in Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Disease. (Oral) Presentation at the 2007 Pediatric Academic Societies’ Annual Meeting (ASPHO). Pediatric Blood and Cancer 2007, 48(6): 604.
	9. \*Hendrickson JE, Roback JD, Hillyer CD, Zimring JC. Sub-types of Inflammation have Differential Effects on Alloimmunization to Red Blood Cells. (Oral) Presentation at the AABB Annual Meeting, 2007. Transfusion 2007, 47 (Supplement): S64-030L.
	10. \*Hendrickson JE, Anderson KM, Zimring JC. The Spleen is Required for Alloimmunization to mHEL RBC Antigen. (Poster) Presentation at the AABB Annual Meeting, 2007. Transfusion 2007, 47(Supplement): SP419.
	11. \*Hendrickson JE, Roback JD, Hillyer CD, Zimring JC. An Intact Spleen is Required for Alloimmunization to Transfused Red Blood Cells due to Intrasplenic Activation of CD4+ T cells. (Oral) Presentation at the 49th American Society of Hematology Annual Meeting, 2007. Blood 2007, 108(11): 453.
	12. \*Zimring JC, Cadwell C, Hendrickson JE, Desmarets M, Neades R, Patel SR, Peterson K. Generation of a Novel Murine Model of RBC Immunology: The HEL-OVA-DUFFY Mouse. (Poster) Presentation at the AABB Annual Meeting, 2008. Transfusion 2008, 48(Supplement): 177A.
	13. \*Kraus T, Gilson C, Hod E, Hendrickson JE, Spitalnik S, Hillyer C, Shaz B, Zimring, C. An Analysis of In Vivo Survival of Murine RBCs Following Storage in CPDA-1. (Oral) Presentation at the AABB Annual Meeting, 2008. Transfusion 2008, 48(Supplement): 37A.
	14. \*Hendrickson JE, Hillyer CD, Zimring, JC. LPS Inhibits Activation and Expansion of CD4+ T Specific for the Transfused mHEL Red Blood Cell Antigen. (Poster) Presentation at the AABB Annual Meeting, 2008. Transfusion 2008, 48(Supplement): 178A.
	15. \*Hendrickson JE, Hillyer CD, Zimring JC. Effects of Inflammation on Alloimmunization to 3 Unique Red Blood Cell Specific Antigens in a Novel Model: The HEL-OVA-DUFFY Mouse. (Poster) Presentation at the AABB Annual Meeting, 2008. Transfusion 2008, 48(Supplement):176A-177A.
	16. \*Hendrickson JE, Cadwell CM, Hillyer CD, Zimring JC. A Novel Model of Autoimmunity to Self Red Blood Cell Antigens. (Poster) Presentation at the 50th American Society of Hematology Annual Meeting, 2008. Blood 2008, 112(11): 3461.
	17. \*Hendrickson JE, Archer DR, Perry JR, Hillyer CD, Zimring JC. Berkeley Mice with Sickle Cell Disease are Not More Immunizable to Transfused HOD Red Blood Cells Than Sickle Trait Control Mice. (Oral) Presentation at the 50th American Society of Hematology Annual Meeting, 2008. Blood 2008, 112(11): 292.
	18. \*Cadwell CM, Smith NH, Hendrickson JE, Zimring JC. Non-Hemolytic Antigen-Loss from RBCs in the Presence of IgM Autoantibodies. (Oral) Presentation at the AABB Annual Meeting, 2009. Transfusion 2009, 49(Supplement): 27A.
	19. \*Hudson KE, Lin E, Hendrickson JE, Lukacher A, Zimring, JC. A Novel Pathway of Enhancing Transfusion-induced RBC Alloimmunization Through Prior Pathogen Exposure. (Oral) Presentation at the AABB Meeting, 2009. Transfusion 2009, 49(Supplement): 27A.
	20. \*Hudson KE, Hendrickson JE, Zimring, JC. Patterns of Deletion of Autoreactive B Cells Specific for RBC Antigens. (Oral) Presentation at the AABB Annual Meeting, 2009. Transfusion 2009, 49(Supplement): 34A.
	21. \*Gilson CR, Cadwell CM, Smith NH, Hendrickson JE, Zimring JC. Alloimmunization Against MHC I on Transfused Blood Does Not Require Donor MHC II Expression. (Oral) Presentation at the AABB Annual Meeting, 2009. Transfusion 2009, 49(Supplement): 6A.
	22. \*Hod EA, Zhang N, Sokol S, Wojczyk BS, Ansaldi D, Sheth S, Zimring JC, Hendrickson JE, Brittenham, GM, Spitalnik SL. Harmful Effects of Red Blood Cell Transfusions: Iron and Inflammation. (Oral Plenary) Presentation at the AABB Annual Meeting, 2009. Transfusion 2009, 49(Supplement): 2A.
	23. \*Hendrickson JE, Hod EA, Spitalnik SL, Hillyer CD, Zimring JC. HOD RBCs Stored for 14 Days are Significantly More Immunogenic Than Fresh HOD RBCs. (Oral) Presentation at the AABB Annual Meeting, 2009. Transfusion 2009, 49(Supplement): 28A.
	24. \*Hendrickson JE, Hod EA, Spitalnik SL, Hillyer CD, Zimring, JC. Leukoreduction Decreases Alloimmunogenicity of Transfused Murine RBCs. (Oral) presentation at the American Society of Hematology Annual Meeting, 2009. Blood 2009, 114(22): 646.
	25. \*Hendrickson JE, Pereira G, Shaz B, Jessup P, Atwell F, Polstra B, and Josephson CD. Development of a Trauma Massive Transfusion Protocol at a Pediatric Medical Center in a Large US Metropolitan Area. (Poster) presentation at the AABB Annual Meeting, 2010. Transfusion 2010(50), supplement.
	26. \*Hendrickson JE, Patel SR, Smith NH, Cadwell CM, Ozato K, Morse H, Yoshimi R, and Zimring JC. Decreased Trim 21 Expression is Not a Variable in Frequency or Magnitude of Alloimmunization to Transfused Murine RBCs. (Oral) presentation at the AABB Annual Meeting, 2010. Transfusion 2010(50), supplement.
	27. \*Hendrickson JE, HOD EA, Cadwell CM, Eisenbarth SC, Spiegel DA, Tormey CA, Spitalnik SL, and Zimring JC. The Effects of Rapid RBC Clearance and Post-Transfusion Cytokine Storm on Alloimmunization in a Murine Model. (Oral) presentation at the AABB Annual Meeting, 2010. Transfusion 2010(50), supplement.
	28. \*Hendrickson JE, Hod EA, Spitalnik SL, Zimring JC. Fresh murine RBCs Abrogate the Enhanced Alloimmunogenicity of Stored Murine RBCs. (Oral) presentation at the American Society of Hematology Annual Meeting, 2010. Blood 2010.
	29. \*Hendrickson JE, Hod EA, Spitalnik SL, Zimring JC. Fresh Murine RBCs Abrogate the Enhanced Alloimmunogenicity of Stored Murine RBCs. (Oral) Presentation in “Highlights of ASH, Latin America: Transfusion Medicine.” 2011.
	30. \*Hudson KE, Hendrickson JE, Cadwell C, Lin E, Iwakoshi NN, Lukacher AE, Zimring JC. Incomplete B Cell Tolerance to Red Blood Cell Antigens. (Poster) presentation at Keystone Immunology Symposium, April 2011.
	31. \*Hendrickson JE, Hod EA, Spitalnik SA, Zimring, JC. Non Responsiveness to Transfused Murine hGPA RBCs Predicts Future Non-Responsiveness in an Antigen Specific Fashion. (Oral) presentation at the AABB Annual Meeting, 2011. Transfusion 2011, supplement.
	32. \*Hendrickson JE, Shaz BH, Pereira G, Atwell F, Jessup P, Atkins E, Johnson KK, Bao G, Easley KA, Josephson CD. Coagulopathy Predicts Adverse Outcomes in Pediatric Trauma Patients and an MTP increases FFP:RBC Ratios. (Oral) presentation at the AABB Annual Meeting, 2011. Transfusion 2011, supplement.
	33. Smith NH, Hod EA, Spitalnik SL, Zimring JC, \*Hendrickson JE. A Novel Murine Model of Pregnancy and Transfusion induced anti-Kell RBC Alloimmunization. (Oral) Presentation at the American Society of Hematology Annual Meeting, 2011. Blood 2011.
	34. \*Hudson KE, Hendrickson JE, Cadwell C, Iwakoshi N, Zimring JC. Central T cell Tolerance and Peripheral B cell tolerance for an RBC Autoantigen are Incomplete in Healthy Mice: Implications for AIHA pathogenesis. (Oral) Presentation at the American Society of Hematology Annual Meeting, 2011. Blood 2011.
	35. Girard-Pierce KR, Stowell SR, Smith NH, Henry KL, Zimring JC, \*Hendrickson JE. Marginal Zone B cells Mediate Alloantibody Formation to a Clinically Significant Human RBC Antigen in a Murine Model. Oral presentation at the ASH Annual Meeting, 2012. Blood 2012.
	36. \*Hendrickson JE, Smith NH, Girard-Pierce KR, Tormey CA, Henry KL, Zimring JC, Stowell, SR. A Murine Model of Weak KEL: Similarities to Weak Rh(D). (Oral) presentation at the ASH Annual Meeting, 2012. Blood 2012.
	37. \*Hendrickson JE, Stowell SR, Smith NH, Girard-Pierce KR, Hudson KE, Zimring JC. Transfused RBCs can be Immunogenic in Splenectomized Mice: of Inflammation, Adjuvants, and Anamnestic Responses. (Oral Plenary) Talk at the AABB Annual Meeting, 2012. Transfusion 2012, 52(Supplement): P1-030A.

* 1. Smith NH, Hod EA, Spitalnik SL, Zimring JC, \*Hendrickson JE. A Novel Murine Model of Pregnancy and Transfusion induced anti-Kell RBC Alloimmunization. (Oral Presentation) by \*D. Siegel in “Highlights of ASH, Latin America: Transfusion Medicine,” 2012.
	2. \*Stowell SR, Girard-Pierce K, Smith NH, Hendrickson JE, Zimring JC. A Novel Role for Complement C3 in Antibody-Induced Antigen Modulation. (Oral) presentation at AABB Annual Meeting, 2013. Transfusion 2013, Supplement.
	3. \*Stowell SR, Arthur CM, Smith NH, Zimring JC, Hendrickson JE. Older RBCs Experience Enhances Clearance Compared to Younger RBCs Following Simple Transfusion. (Poster) presentation at AABB Annual Meeting, 2013. Transfusion 2013, Supplement.
	4. Wang T, Kin T, Padukkavidana T, Smith NH, Stowell SR, Eisenbarth S, Zimring JC, Spiegel DA, \*Hendrickson JE. ALT-711, which Breaks Advanced Glycation End Products, Improves Murine RBC Storage. (Poster) presentation at AABB Annual Meeting, 2013. Transfusion 2013, Supplement.

* 1. Yu H, Stowell SR, Hendrickson JE, Zimring JC, Uchikawa M, \*Lazarus AH. Inhibition of RBC Alloimmunization Can Occur Independently from Red Cell Clearance in A Murine Model. Oral presentation at AABB Annual Meeting, 2013. Transfusion 2013, Supplement.
	2. Sullivan HC, Girard-Pierce KR, Arthur CM, Smith NH, Fantz CR, Zimring JC, Hendrickson JE, \*Stowell SR. Clearance of KEL RBCs by anti-KEL antibodies. (Oral) presentation and winner of Paul E. Strandjord Young Investigator’s Award at the Academy of Clinical Physicians and Scientists Annual Meeting, 2013.
	3. \*Stowell SR, Arthur CM, McBride R, Smith DF, Hendrickson JE, Winkler AM, Paulson JC, Cummings RD. Microbial Microarray identifies Innate Immunity against Molecular Mimicry. (Oral) Presentation at the Academy of Clinical Physicians and Scientists Annual Meeting, 2013.
	4. \*Stowell SR, Girard-Pierce KR, Arthur CM, Smith NH, Hendrickson JE, Zimring JC. Fcgamma Receptors Protect Cells by Selective Removal of Target Antigen. (Oral) presentation at the Academy Clinical Physicians and Scientists Annual Meeting, 2013.
	5. \*Stowell SR, Girard-Pierce KR, Arthur CM, Smith NH, Winkler AM, Zimring JC, Hendrickson JE. Depletion of Marginal Zone B-cells inhibits RBC Alloimmunization. (Oral) presentation of Paul E. Strandjord Young Investigator’s Award at the Academy of Clinical Physicians and Scientists Annual Meeting, 2013.
	6. \*Stowell SR, Arthur CM, Girard-Pierce KR, Sullivan HC, Santhanakrishnan M, Natarajan P, Patel SR, Tormey CA, Zimring JC, Hendrickson JE. Polyclonal Anti-KEL (KELGam) Prevents Alloimmunization to Transfused KEL RBCs in a Murine Model. (Oral) presentation at ASH Annual Meeting, 2014. Blood 2014, Supplement.
	7. Ryder AB, Hendrickson JE, \*Tormey, CA. Chronic Inflammatory Autoimmune Disorders are a Risk Factor for Blood Group Alloimmunization in Transfused Patients. (Poster) presentation at ASH Annual Meeting, 2014. Blood 2014, Supplement.
	8. \*Hod EA, Francis RO, Hendrickson JE, Prestia K, Bandyopadhyay S. Iron Status Affects the Pro-Inflammatory Cytokine Response to Transfused Stored Red Cells But Does Not Affect Alloimmunogenicity. (Oral) presentation at ISBT Annual Meeting in Seoul Korea, June 2014.
	9. \*Gehrie EA, Hendrickson JE, Tormey CA. Quantitative Assessment of Peri-Transfusion Vital Signs and Infusion Rates to Determine "Expected" Variations in These Parameters. (Poster) presentation at AABB Annual Meeting, 2014. Transfusion 2014, Supplement.
	10. \*Hudson KE, Hendrickson JE, Zimring JC. Inflammation Significantly Alters Splenic Composition and Erythrophagocytosis. (Oral) presentation AABB Annual Meeting, 2014. Transfusion 2014, Supplement.
	11. \*Stowell SR, Smith NH, Girard-Pierce KR, Arthur CM, Zimring JC, Hendrickson JE. Impact of Paternal KEL2 RBC Antigen Density on Maternal Alloimmunization and Fetal Outcomes in a Murine Model of HDFN. (Oral) presentation AABB Annual Meeting, 2014. Transfusion 2014, Supplement.
	12. \*Stowell SR, Arthur CM, Smith NH, Zimring JC, Hendrickson JE. Impact of RBC Copy Number and Dose on Murine Immune Responses to Transfused KEL RBCs. (Plenary oral) presentation AABB Annual Meeting, 2014. Transfusion 2014, Supplement.
	13. Yoo J, Arthur CM, Zena P, Girard-Pierce KR, Hendrickson JE, \*Stowell SR. Antigen Density Impacts RBC Survival and Antigen Modulation Following Incompatible RBC Transfusion. (Poster) presentation at ASH Annual Meeting, 2015.Blood 2015;126: 2350 supplement.
	14. \*Sullivan HC, Arthur CM, Patel SR, Hendrickson JE, Lazarus AH, Stowell SR. Anti-RhD Mediates Loss of RhD Antigen following anti-RhD Infusion. (Oral) presentation at ASH Annual Meeting, 2015. Blood 2015;126: 3570 supplement.

* 1. \*Celli R, Schulz W, Hendrickson JE, Tormey CA. Use of a Novel Network Analysis Tool to Examine Relationships between Disease States and RBC Alloimmunization. (Poster) presentation at ASH Annual Meeting, 2015. Blood 2015 supplement.
	2. Tormey CA, Santhanakrishnan M, Smith NH, Marschner S, Goodrich RP, \*Hendrickson JE. The Effect of Riboflavin/UV-light Pathogen Inactivation on Post-Transfusion RBC Recovery, Survival, and Alloimmunization. (Poster) presentation at AABB Annual Meeting, 2015. Transfusion 2015 supplement.
	3. Santhanakrishnan M, Tormey CA, Natarajan P, \*Hendrickson JE. Anti-KEL RBC Alloantibodies are Transferred in Breast Milk and are Capable of Causing RBC Clearance in a Murine Model. (Oral) presentation at AABB Annual Meeting, 2015. Transfusion 2015 supplement.
	4. \*Gibb DR, Liu J, Santhanakrishnan M, Natarajan P, Iwasaki A, Hendrickson JE. Type 1 Interferon Regulates Inflammation Associated RBC Alloimmunization by Promoting Monocyte Derived Dendritic Cell Erythrophagocyosis in Mice. (Oral) abstract presentation at the ASH Annual Meeting, 2016. Blood 2016 supplement.
	5. \*Ansare M, Hendrickson JE, Tormey CA. Determination of RBC Alloimmunization Rates in Patients with Hematologic and Oncologic Malignancies. (Poster) presentation at the ASH Annual Meeting, 2016. Blood 2016 supplement.
	6. \*Hendrickson JE, Roubinian N, Chowdhur D, Brambilla D, Murphy E, Wu Y, Ness P, Gehrie E, Snyder E, Hauser RG, Gottschall J, Klineman S, Kakaiya R, Strauss R. Incidence of Transfusion Reactions: a Multi-center Study utilizing Systematic Active Surveillance and Expert Adjudication. (Oral) abstract presentation at the AABB Annual Meeting. Transfusion 2016 supplement.
	7. Scott M, Garcia C, Hendrickson JE, \*Tormey CA. Rh-positive Platelet units are Associated with Low Rates of anti-D Development in Rh-Negative Male Patients. (Oral) abstract presentation at the AABB Annual Meeting. Transfusion 2016 supplement.
	8. Liu J, Santhanakrishnan M, Gibb DR, Natarajan P, Stowell SR, \*Hendrickson JE. Modulation of the KEL Glycoprotein on Transfused Murine RBCs Appears Critical for Passively Administered KELIg to Prevent Alloimmunization. (Oral) abstract presentation at the AABB Annual Meeting. Transfusion 2016 supplement.
	9. \*Gibb DR, Santhanakrishnan M, Nararajan P, Liu J, Patel S, Stowell SR, Iwaski A, Hendrickson JE. B-cells Require Type 1 IFN Signalizing to Produce Alloantibodies to Transfused KEL-expressing RBCs in Mice. (Oral) abstract presentation (outstanding trainee) at the AABB Annual Meeting. Transfusion 2016 supplement.
	10. \*Roubinian N, Escobar G, Gardner M, Triulzi DJ, Hendrickson JE, Gottschall J, Murphy E. Epidemiology of Platelet Transfusion in Hospitalized Patients: data from an integrated health care delivery system. (Poster) abstract presentation at the AABB Annual Meeting. Transfusion 2016 supplement.
	11. \*Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Kleinman S, Hendrickson JE. Epidemiologic Characterization of Transfusion Recipients with Red Blood Cell Antibodies from Four US regions: Evidence from the REDS-III Recipient Database. (Poster) presentation at the ASH Annual Meeting, 2017. Blood 2017 supplement.
	12. Stahl M, Komrokji RS, Stone RM, Erba HP, Gore SD, Litzow MR, Zeidan AM, Sekeres MA, Steensma DP, Hendrickson JE, Kim TK, Luger S, \*Pine A. Beliefs and Patterns of Practice in the Management of Hyperleukocytosis among Health Care Providers for Patients with Acute Leukemia: a Large North American Web-based Survey. (Poster) presentation at the ASH Annual Meeting, 2017. Blood 2017 supplement.
	13. \*Curtis SA, Brandow AM, Hendrickson JE, Deveaux M, Zelterman D, Roberts JD, Devine L. Chronic Red Blood Cell Exchange Transfusion Therapy does not Impact Hospital Utilization or ASCQ-ME Pain Domains in Adults Living with Sickle Cell Disease. (Poster) presentation at the ASH Annual Meeting, 2017. Blood 2017 supplement.
	14. \*Roubinian NH, Hendrickson JE, Triulzi DJ, Gottschall J, Michalkiewicz, Chowdhury D, Kor DJ, Looney MR, Matthays M, Kleinman S, Brambilla D, Murphy E. Risk Factors and Outcomes

of Transfusion associated Circulatory Overload during a Period of Decreased Blood Utilization. (Oral) presentation at the AABB Annual Meeting, 2017. Transfusion 2017 supplement.

* 1. \*Gehrie EA, Roubinian NH, Chowdhury D, Brambilla D, Murphy E, Gottschall J, Wu Y, Ness P, Strauss R, Hendrickson JE. A Multi-center Study Investigating Vital Sign Changes occurring in Complicated and Uncomplicated Transfusions. (Oral) presentation at the AABB Annual Meeting, 2017. Transfusion 2017 supplement.
	2. \*Baine I, Bahar B, Hendrickson JE, Hudson KE, Tormey CA. Microbial Pathogen Primary Sequence Correlates with Blood Group Antigen Immunogenicity. (Oral) presentation (outstanding trainee) at the AABB Annual Meeting, 2017. Transfusion 2017 supplement.
	3. Patel SR, Bennett A, Girard-Pierce K, Arthur C. Mener A, Zerra P, Tormey CA, Hendrickson JE, \*Stowell SR. Primed CD4 T cells to One RBC Antigen can Enhance Subsequent Alloimmunization. (Oral) presentation at the AABB Annual Meeting 2017. Transfusion 2017 supplement.
	4. \*Gehrie EA, Spencer BR, Merenda S, Gokhale A, Palmarozza R, Hendrickson JE, Ross R, Snyder EL. Phased Integration of Pathogen Reduced Platelets into Inventory at a US Academic Medical Center: Preliminary Assessment of Impact on Pediatric Patient Care. (Poster) Presentation at the AABB Annual Meeting, 2017. Transfusion 2017 supplement.
	5. \*Gibb DR, Liu J, Natarajan P, Santhanakrishnan M, Madrid DJ, Eisenbarth SC, Zimring JC, Iwasaki A, Hendrickson JE. Type 1 Interferon is Necessary and Sufficient for Alloimmunization to Transfused KEL-Expressing RBCs in Mice. (Oral) abstract presentation at the Academy of Clinical Laboratory Physicians and Scientists Annual Meeting, 2017.
	6. \*Madrid DJ, Gibb DR, Natarajan PR, Santhanakrishnan M, Liu J, Hendrickson JE. The Importance of CD4 cells and CD40/CD40L Interactions in Humoral Immune Responses to Transfused KEL RBCs in Mice. (Oral) abstract presentation at the Academy of Clinical Laboratory Physicians and Scientists Annual Meeting, 2017.
	7. \*Gibb DR, Liu D, Liu J, Santhanakrishnan M, Eisenbarth SC, Hendrickson JE. Influenza Infection Induces RBC Alloimmunization by a Type 1 interferon Dependent Mechanism. (Oral) presentation at the ASH Annual Meeting, 2018. Blood 2018 supplement.
	8. \*Nickel RS, Horan JT, Abraham A, Qayad M, Haight A, Luban N, Hendrickson JE. HLA Class I Alloantibodies and Platelet Transfusion Support in HLA-identical Bone Marrow Transplantation for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. (Poster) presentation at the ASH Annual Meeting, 2018. Blood 2018 supplement.
	9. \*Curtis SA, Balbuena-Merle R, Roberts J, Devine L, Zelterman D, Dearborn-Tomazos J, Sansing L, Hendrickson JE. Elevated Levels of CD64 MFI on Monocyte Subsets are associated with a History of Stroke in Sickle Cell Disease. (Poster) presentation at the ASH Annual Meeting, 2018. Blood 2018 supplement.
	10. \*Roubinian NH, Chowdhury D, Hendrickson JE, Triulzi DJ, Gottschall JL, Kor DJ, Looney MR, Matthay MA, Kleinman SH, Brambilla D, Murphy EL for the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Classification Tree Algorithms to Identify Patients at Risk for Transfusion-associated Circulatory Overload. (Poster) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.
	11. \*Roubinian NH, Keating S, Hendrickson JE, Triulzi DJ, Gottschall JL, Michalkiewicz M, Chowdhury D, Kor DJ, Looney MR, Matthay MA, Kleinman SH, Brambilla D, Murphy EL, for the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) Utility of NT-ProBNP Levels in the Differential Diagnosis of Pulmonary Transfusion Reactions. (Poster) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.
	12. Arneja A, Salazar J, Santhanakrishnan M, Hendrickson JE, \*Luckey CJ. Red Blood Cell Alloimmunization Responses to Transfused Blood do not Require Splenic Marginal Zone Macrophages. (Oral) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.
	13. \*Balbuena-Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CL, Tormey CA, Siddon A, Roberts JD, Hendrickson JE. Red Blood Cell Alloimmunization is Associated with Lower CD64 Expression on Monocyte Subsets in Patients with Sickle Cell Disease. (Oral) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.
	14. \*Gibb DR, Pelland K, Hendrickson JE, Tormey CA. Examining the Correlation between Hepatitis C Infection, Interferon therapy, and Red Blood Cell Alloimmunization in Humans. (Poster) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.

* 1. \*Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence of Red Blood Cell Antibodies in Donors at 4 US Blood Centers. (Poster) presentation at the AABB Annual Meeting, 2018. Transfusion 2018 supplement.
	2. \*Balbuena-Merle R, Hauser RG, Karafin MS, Tan S, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottshcall JL, Tormey CA, Hendrickson JE. The Presence and Persistence of Pregnancy-associated Red Blood Cell Alloantibodies in Blood Donors. (Poster) presentation at the ASH Annual Meeting, 2019. Blood 2019 supplement.
	3. \*Madany E, El Kadi N, Pandya S, Hendrickson JE, Gibb DR. Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization. (Oral) presentation at the ASH Annual Meeting, 2019. Blood 2019 supplement.
	4. \*Gupta GG, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ count for Autologous Peripheral Blood Stem-cell Collection. (Poster) presentation at the ASFA Annual Meeting, 2020.
	5. \*Patel RM, Hendrickson JE, Nellis ME, Birch R, Goel R, Karam O, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson, Sola-Visner M, for the NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Variation in Neonatal Transfusion Practice in the United States. (Poster) presentation at the AABB Annual Meeting, 2020. Transfusion 2020 supplement.
	6. \*Nellis ME, Goel R, Hendrickson JE, Birch R, Patel RM, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Sola-Visner , Josephson CD, Karam O, for the NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Pediatric Transfusion Practice in the United States. (Oral) presentation at the AABB Annual Meeting, 2020. Transfusion 2020 supplement.
	7. \*Manrai P, Siddon AJ, Hager K, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 Associated with Silenced Kidd Antigen Expression & a Novel Single Nucleotide Variant of the JK Gene. (Poster) presentation at the AABB Annual Meeting, 2020. Transfusion 2020 supplement.
	8. Escamilla-Rivera V, Santhanakrishnan M, Liu J, Gibb DR, Eisenbarth SC, Luckey J, Zimring JC, Hudson KE, Stowell SR, \*Hendrickson JE. Complement Plays a Critical Role in Inflammation induced Immunoprophylaxis Failure in Mice. (Oral) Plenary presentation at the AABB Annual Meeting, 2021. Transfusion 2021 supplement.

27. Research Focus: My work focuses on better understanding RBC alloantibody development, evanescence, and clinical sequelae, considering blood donor, blood component, and transfusion recipient variables. My long-term goals are to develop strategies to minimize RBC alloimmunization and complications, through a bench to bedside and back approach.

28. Patents: None

29. Grant Support:

1. Active Support:
2. Federally Funded Grants:

Role: PI

Source: NIH/NHLBI

Award Type: R01 HL132951-01A1

Title: “Responsiveness and Non-Responsiveness to Transfused RBCs in Mice and Humans”

Amount: $250,000/year direct costs

Years: 8/1/2017-5/31/2023 (in no-cost extension period)

1. Contracts

Role: PI

Source: NIH/NHLBI

Award Type: Contract, HHSN26819HB00003R/75N92019D000036

Title: “Recipient Epidemiology and Donor Evaluation Study-IV-P (REDS-IV-P)”

Amount: $1,057,142/year

Years: 4/1/2019-3/31/2026

Role: Investigator

Source: Health and Human Services, Office to the Assistant Secretary of Health

Award Type: Contract to 501(c)3

Title: “Red Blood Cell Antibody Exchange across US-Hospitals for Patient Safety”

Amount: $185,000 total

Years: 2022-2024

1. Previous Support:

Role: PI

 Source: National Blood Foundation

 Award Type: Private Foundation Funded

Title: “The Effect of Host Inflammation on Alloimmunization to Red Blood Cell Transfusion”

Amount: $65,000/year

Years: 2006-2008

Role: Awardee

Source: NIH/NHLBI

Award Type: Institutional T32

Title: “Transfusion Medicine”

Amount: $55,000/year

Years: 2007-2008

Role: PI

Source: American Society of Hematology

Award Type: Private Foundation Funded

Title: “Regulation of Red Blood Cell Alloimmunization by

Different Subtypes of Recipient Inflammation”

Amount: $50,000/year

Years: 2008-2010

Role: PI

Source: Emory Egleston Children’s Research Center

Award Type: Private Funding

Title: “Effects of Storage on the Immunogenicity of Transfused Red Blood Cells”

Amount: $50,000

Year: 2009-2010

Role: PI

Source: NIH (National Heart, Lung, Blood Institute)

Award Type: K08 HL092959

Title: “Regulation of RBC Alloimmunization by Different Types

of Recipient Inflammation”

Amount: $119,000/year

Years: 2009-2013

Role: PI

Source: Emory Egleston Children’s Research Center

Award Type: Private Funding

Title: “Development and Characterization of a Novel Mouse Model Containing an Authentic Human RBC Antigen”

Amount: $50,000

Year: 2011-2012

Role: PI

Source: Emory University Research Council

Award Type: Institutional Funding

Title: “Advanced Glycation End Products on Transfused RBCs

An Unappreciated Danger?”

Amount: $30,000/year

Years: 2012-2013

Role: PI

Source: Children’s Pediatric Research Center for Transplant Immunology and Immune Therapeutics

Award Type: Institutional Funding

Title: “Transfusion Related Alloimmunization to Minor Histocompatibility Antigens in Sickle Cell Disease”

Amount: $50,000/year

Years: 2012-2013

Role: Co-I (with Patricia Denning)

Source: Children’s Pediatric Research Center for Immunology and Vaccines

Award Type: Institutional Funding

Title: “Red Blood Cell Transfusion Associated Necrotizing Enterocolitis”

Amount: $50,000/year

Years: 2012-2013

Role: PI

Source: NIH (National Heart, Lung, Blood Institute)

Award Type: R21 HL114696

Title: “Immunoprophylaxis to Kell RBC Alloimmunization

During Pregnancy”

Amount: $150,000/year

Years: 2012-2014

Role: PI

Source: Emory + Children’s Pediatric Research Center

Award Type: Institutional Funding

Title: “Antigen Specific Non-Responsiveness Following RBC Transfusion: An Unexpected Benefit”

Amount: $45,000/year

Years: 2013-2014

Role: PI

Source: Terumo BCT Blood Safety Innovation Award

Award Type: Industry Funding

Title: “The Effect of Mirasol Treatment on RBC Alloimmunization in a Murine Model”

Amount: $100,000/year

Years: 2013-2014

Role: Co-I

Source: Emory + Children’s Pediatric Research Center

Award Type: Institutional Funding

Title: “An Investigation of Coagulopathy after Severe Traumatic Brain Injury in Children with Emphasis on the Role of Platelet Dysfunction”

Amount: $50,000/year

Years: 2013-2014

Role: PI

Source: Industry Funding (Terumo BCT)

Award Type: Blood Safety Innovation Award

Title: “The Effect of Mirasol Treatment on RBC Alloimmunization in a Murine Model”

Award: $100,000/year

Years: 2013-2015

Role: Co-I (PI Snyder)

Source: NIH/NHLBI

Award Type: Contract HHSN268201100006I/HHSN26800002

Title: “Recipient Epidemiology and Donor Evaluation Study III (REDS-III)”

Award: $725,591/year

Years: 2013-2019

Role: PI

Source: NIH/NHLBI

Award Type: R01 HL126076

Title: “Protecting Fetuses and Newborns from Maternal RBC Alloantibodies”

Amount: $250,000/year

Years: 2014-2020

Role: Co-I

Source: NIH/NHBLI

Award Type: R01 HL124078

Title:“Red Cell Transfusion-associated Necrotizing Enterocolitis in Premature Infants”

Award: $16,752/year

Years: 2015-2018

Role: Director of Enrichment Program (PI Krause and Gallagher)

Source: NIH/NIDDK

Award Type: U54 DK106857-01

Title: “Yale Cooperative Hematology Specialized Core Center”

Amount: $600,000/year

Years: 2015-2022 (continuing through 2025 at Yale)

Role: PI

Source: NIH/NIDDK

Award Type: Pilot and Feasibility Grant Program of the Yale Cooperative Hematology Specialized Core Center’s U54

Title: “An Investigation of Red Blood Cell Antigen Modulation”

Award: $20,000/year

Years: 2016-2018 (no cost extension in 2018)

Role: PI of Core B (P01 PI Zimring)

Source: NIH/NHLBI

Award Type: P01 HL132819-A1

Title: “Immunobiology of Transfusion”

Amount: $240,000/year

Years: 2017-2022

Role: Co-I of Project 3 (PI Eisenbarth, P01 PI Zimring)

Source: NIH/NHLBI

Award type: P01 HL132819-A1

Title: “Immunobiology of Transfusion”

Amount: $250,000/year

Years: 2017-2022

Role: Co-I (PI Tormey)

Source: Collage of American Pathology Foundation

Award Type: Rippey Grant

Title: “Immunologic and Hemostatic Evaluation of COVID-19 Convalescent Plasma and Correlation with Transfused Recipient Outcomes”

Amount: $13,000/year

Years: 2020-2021

Role: Blood Bank Co-I (PI Dessruisseaux)

Source: BARDA and NIH

Award Type: Multi-Center Study

Title: “Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-Sars-Cov-2 Plasma to Placebo in Covid-19 Hospitalized Patients” (CONTAIN)

Amount: No salary

Years: 2020-2021

Role: PI (Multi-PI with Gallagher)

Source: NIH/NIDDK

Award Type: R01 DK111539-01A1

Title: “Novel Mechanisms of Congenital Dyserythropoietic

Anemia”

Amount: $250,000/year

Years: 2020-2022 (continuing through 2024 at Yale)

30. Bibliography

1. Published and Accepted Research Articles (clinical, basic science, other) in

 Refereed Journals:

1. **Hendrickson JE**, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, Zimring JC. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006; 46(9): 1526-1536.
2. **Hendrickson JE**, Chadwick TE, Roback JD, Hillyer CD, Zimring JC. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic Cells. Blood 2007; 110(7): 2736-2743.
3. **Hendrickson JE,** Roback JD, Hillyer CD, Easley KA, Zimring JC. Discrete toll like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion 2008; 48(9), 1869-1877.
4. **Hendrickson JE**, Saakadze N, Cadwell CM, Upton JW, Mocarski ES, Hillyer CD, Zimring JC. The spleen plays a critical role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion 2009, 48(9): 1678-1684.
5. Gilson CR, Kraus T, Hod EA, **Hendrickson JE**, Spitalnik SL, Hillyer CD, Shaz BH, Zimring JC. A novel mouse model of red blood cell storage and post-transfusion in vivo survival. Transfusion 2009, 48(9): 1546-1553.
6. Gilson CR, Cadwell CM, Smith NH, **Hendrickson JE**, Zimring JC. MHC II on transfused murine blood is not required for alloimmunization against MHC I. Vox Sanguinis, 2010 Nov; 99(4): 369-374.
7. Hod EA, Zhang N, Sokol SA, Wojczyk BS, Francis RO, Ansaldi D, Francis KP, Della-Latta P, Whittier S, Sheth S, **Hendrickson JE**, Zimring JC, Brittenham GM, Spitalnik SL. Transfusion of RBCs after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood, 2010 May 27; 115(21): 4284-4292.
8. Hod EA, Arinsburg S, Francis R, **Hendrickson JE**, Zimring JC, Spitalnik SL. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sanguinis, 2010 Aug 1; 99(2): 99-111.
9. Hudson KE, Lin E, **Hendrickson JE**, Lukacher AE, Zimring JC. Regulation of primary alloantibody response through antecedent exposure to a microbial T cell epitope. Blood 2010 May 13; 115(19): 3989-3996.
10. **Hendrickson JE**, Hod EA, Spitalnik SL, Hillyer CD, Zimring, JC. Storage of murine RBCs enhances alloantibody responses to an erythroid specific model antigen. Transfusion 2010, 50(3): 642-648.
11. **Hendrickson JE**, Hod EA, Hudson KE, Spitalnik SL, Zimring JC. Transfusion of fresh murine red blood cells reverses adverse effects of older stored red blood cells. Transfusion, 2011 Dec; 51(12): 2695-2702.
12. **Hendrickson JE,** Hod EA, Cadwell CM, Eisenbarth SC, Spiegel DA, Tormey CA, Spitalnik SL, Zimring JC. Rapid clearance of transfused murine RBCs is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion, 2011 Nov; 51(11): 2445-2454.
13. Patel SR, **Hendrickson JE**, Smith NH, Cadwell CM, Ozato K., Morse HC, Yoshimi R, Zimring JC. Alloimmunization against RBC or PLT antigens is independent of TRIM21 expression in a murine model. Molecular Immunology, 2011 March; 48 (6-7): 909-913.
14. Smith NH, Hod EA, Spitalnik SL, Zimring JC, **Hendrickson JE.** Transfusion in the absence of inflammation induces antigen specific tolerance to murine RBCs. Blood, 2012 Feb 9; 119(6): 1566-1569.
15. Hod EA, Brittenham GM, Billote GB, Francis RO, Ginzburg YZ, **Hendrickson JE,** Jhang J, Schwartz J, Sharma S, Sheth S, Sireci AN, Stephens HL, Stotler BA, Wojczyk BS, Zimring JC, Spitalnik SL. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood, 2011 Dec 15; 118(25): 6675-6682.
16. **Hendrickson JE**, Shaz BH, Pereira G, Atkins E, Johnson KK, Bao G, Easley KA, Josephson CD. Coagulopathy is prevalent and associated with adverse outcomes in transfused pediatric trauma patients. J Peds, 2012 Feb; 160(2): 204-209.e3.
17. Smith NH, Henry KL, Cadwell CM, Bennett A, **Hendrickson JE**, Frame T, Zimring JC. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion, 2012 Dec; 52(12): 2620-2630.
18. Hudson KE, **Hendrickson JE**, Cadwell CM, Iwakoshi NN, Zimring JC. Partial tolerance of autoreactive B and T cells to erythrocyte-specific self-antigens in mice. Haematologica, 2012 Dec; 97(12): 1836-1844.
19. **Hendrickson JE,** Hod EA, Perry J, Chappa P, Adisa O, Kean LS, Ofori-Acquah

S, Archer DA Spitalnik SL, Zimring JC. Alloimmunization to transfused HOD

 RBCs is not increased in mice with sickle cell disease. Transfusion, 2012 Feb;

52(2): 231-240.

1. **Hendrickson JE**, Shaz BH, Pereira G, Parker PM, Jessup P, Atwell F, Polstra B,

Atkins E, Johnson KK, Bao G, Easley KA, Josephson CD. Implementation of a

pediatric trauma massive transfusion protocol: a quality improvement initiative.

Transfusion, 2012 June; 52(6): 1228-1236.

1. Francis RO, Jhang J, **Hendrickson JE**, Zimring JC, Hod EA, Spitalnik SL. Frequency of glucose-6-phosphate dehydrogenase deficient packed red blood cell units in a metropolitan transfusion service. Transfusion, 2013 Mar; 53(3): 606-11.
2. Stowell SR, Girard-Pierce KR, Smith NH, Henry KL, Arthur CM, Zimring JC, **Hendrickson JE**. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion, 2014 Jan;54(1): 179-189.
3. Stowell SR, Henry KL, Smith NH, Hudson KE, Halverson GR, Park JC, Bennett AM, Girard-Pierce KR, Arthur CM, Bunting ST, Zimring JC, **Hendrickson JE**. Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood, 2013 Aug 22; 122(8): 1494-1504.
4. Zimring JC, Smith N, Stowell SR, Johnsen JM, Bell LN, Francis RO, Hod EA, **Hendrickson JE**, Roback JD, Spitalnik SL. Strain-specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model. Transfusion, 2014; 54: 137-148.
5. Girard-Pierce KR, Stowell SR, Smith NH, Arthur CM, Sullivan HC, **Hendrickson JE**, Zimring JC. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood, 2013 Sept 5; 122(10): 1793-17801.
6. Stowell SR, Liepkalns JS, **Hendrickson JE**, Girard-Pierce KR, Smith NH, Arthur CM, Zimring JC. Antigen modulation confers protection to red blood cells from antibody through Fcγ Ligation. J Immunol, 2013 Nov 15; 191 (10): 5013-5025.
7. Nickel RS, **Hendrickson JE**, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease. Blood 2014; 121: 861-866.
8. Yu H, Stowell SR, Bernardo L, **Hendrickson JE**, Zimring JC, Amash A, Uchikawa M, Lazarus AH: Antibody-mediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model. J Immunol 2014;193: 2902-2910.
9. Krause PJ\*, **Hendrickson JE\*** (co-first authors), Steeves TK, Fish D. Blood transfusion transmission of the tick-borne relapsing fevers spirochete Borrelia miyamotoi in mice. Transfusion 2015 Mar; 55(3): 593-597.
10. Nickel RS, Osunkwo I, Garrett A, Robertson J, Archer DR, Promislow DE, Horan JT, **Hendrickson JE**, Kean LS. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. Br J Hematol. 2015 May; 169(4): 574-83.
11. Gehrie EA, **Hendrickson JE**, Tormey CA. Variation in vital signs resulting from blood transfusion administration in adults. Transfusion. 2015 Aug;55(8):1866-1871.
12. Nickel RS, **Hendrickson JE**, Yee MM, Bray RA, Gebel HM, Kean LS, Miklos DB, Horan JT. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Br J Hematol. Br J Haematol. 20 Jul;170(2):247-256.
13. Stowell SR, Arthur CM, Girard-Pierce KR, Sullivan HC, Santhanakrishnan M, Natarajan P, Patel SR, Tormey CA, Zimring JC, **Hendrickson JE**. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica. 2015 Oct;100(10):e394-397.
14. Nickel RS, Horan JT, Fasano RM, Meyer EKG, Josephson CD, Winkler AM, Yee MEM, Kean LS, **Hendrickson JE**. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion therapy. American Journal of Hematology. 2015 Dec;90(12):1135-1141.
15. Gehrie EA, **Hendrickson JE**, Tormey CA. Measuring the influence of blood component infusion rate on recipient vital signs. Vox Sanguinis. 2015 Nov; 109(4): 353-358.
16. Ryder AB, **Hendrickson JE**, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematogy. 2016 Aug;174(3):483-485.
17. Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, **Hendrickson JE**. Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion. 2016 Apr;56(4):863-872.
18. Arthur CM, Patel SR, Sullivan HC, Winkler AM, Tormey CA, **Hendrickson JE**, Stowell SR. CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood. 2016 Apr 7;127(14):1823-1827.
19. Richards AL, **Hendrickson JE**, Zimring JC, Hudson KE. Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion. 2016 Apr;56(4):905-916.
20. Santhanakrishnan M, Tormey CA, Natarajan P, Liu J, **Hendrickson JE**. Clinically significant anti-KEL RBC alloantibodies are transferred by breast milk in amurine model. Vox Sang. 2016 Jul;111(1):79-87.
21. Gibb DR, Calabro S, Liu D, Tormey CA, Spitalnik SL, Zimring JC, **Hendrickson JE**, Hod EA, Eisenbarth SC. The Nlrp3 inflammasome does not regulate alloimmunization to transfused red blood cells in mice. EBioMedicine. 2016 Jul;9:77-86.
22. Nickel RS, Winkler AM, Horan JT, **Hendrickson JE**. Leukoreduced red blood cell transfusions do not induce platelet glycoprotein antibodies in patients with sickle cell disease. Transfusion. 2016 Sep;56(9):2267-2273.
23. Calabro S, Gallman A, Gowthaman U, Liu D, Chen P, Liu J, Krishnaswamy JK, Nascimento MS, Xu L, Patel SR, Williams A, Tormey CA, Hod EA, Spitalnik SL, Zimring JC, **Hendrickson JE**, Stowell SR, Eisenbarth SC. Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med. 2016 May 30;213(6):887-896.
24. Arneja A, Salazar JE, Jiang W, **Hendrickson JE**, Zimring JC, Luckey CJ. Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica. 2016 Nov;101(11):e440-e444.
25. Liu J, Santhanakrishnan M, Natarajan P, Gibb DR, Eisenbarth SC, Tormey CA, Siddon AJ, Stowell SR, Branch DR, **Hendrickson JE**. Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood. 2016 Dec 29;128(26):3159-3168.
26. **Hendrickson JE**, Roubinian NH, Chowdhury D, Brambilla D, Murphy EL, Wu Y, Ness PM, Gehrie EA, Snyder EL, George Hauser R, Gottschall JL, Kleinman S, Kakaiya R, Strauss RG; National Heart, Lung, and Blood Institute (NHLBI) RecipientEpidemiology and Donor Evaluation Study (REDS-III). Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016 Oct;56(10):2587-2596.
27. Roubinian NH, **Hendrickson JE**, Triulzi DJ, Gottschall JL, Chowdhury D, Kor DJ, Looney MR, Matthay MA, Kleinman SH, Brambilla D, Murphy EL; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm. Vox Sang. 2017 Jan;112(1):56-63.
28. Natarajan P, Liu J, Santhanakrishnan M, Gibb DR, Slater LM, **Hendrickson JE**. Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Transfusion. 2017 Jan;57(1):82-92.
29. Cheng C, Tormey CA, **Hendrickson JE**. Limitations of a scoring model to predict thrombotic thrombocytopaenic purpura. Vox Sang. 2017 Feb;112(2):185-186.
30. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, **Hendrickson JE**, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion. 2017 Feb;57(2):289-295.
31. Arthur CM, Patel SR, Smith NH, Bennett A, Kamili NA, Mener A, Gerner-Smidt C, Sullivan HC, Hale JS, Wieland A, Youngblood B, Zimring JC, **Hendrickson JE**, Stowell SR. Antigen density dictates immune responsiveness following red blood cell transfusion. J Immunol. 2017 Apr 1;198(7):2671-2680.
32. Tormey CA, **Hendrickson JE**. Irradiation of red blood cells and alloimmunization. Lab Med. 2017 May 1;48(2):172-177.
33. Celli R, Schulz W, **Hendrickson JE**, Tormey CA. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sang. 2017 Jul;112(5):469-472.
34. Natarajan P, Santhanakrishnan M, Tormey CA, **Hendrickson JE**. The impact of vaccination on RBC alloimmunization in a murine model. Vox Sang. 2017 Aug;112(6):598-600.
35. Gibb DR, Liu J, Natarajan P, Santhanakrishnan M, Madrid DJ, Eisenbarth SC, Zimring JC, Iwasaki A, **Hendrickson JE**. Type I IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice. J Immunol. 2017 Aug 1;199(3):1041-1050.
36. Natarajan P, Liu D, Patel SR, Santhanakrishnan M, Beitler D, Liu J, Gibb DR, Liepkalns JS, Madrid DJ, Eisenbarth SC, Stowell SR, **Hendrickson JE**. CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model. Front Immunol. 2017 Aug 7;8:907.
37. Schofield JR, **Hendrickson JE**. Autoimmunity, autonomic neuropathy, and the HPV vaccination: A vulnerable subpopulation. Clin Pediatr (Phila). 2018 May;57(5):603-606.
38. Gibb DR, Liu J, Santhanakrishnan M, Natarajan P, Madrid DJ, Patel S, Eisenbarth SC, Tormey CA, Stowell SR, Iwasaki A, **Hendrickson JE**. B cells require Type 1 interferon to produce alloantibodies to transfused KEL-expressing red blood cells in mice. Transfusion. 2017 Nov;57(11):2595-2608.
39. Richards AL, Howie HL, Kapp LM, **Hendrickson JE**, Zimring JC, Hudson KE. Innate B-1 B cells are not enriched in red blood cell autoimmune mice: Importance of B cell receptor transgenic selection. Front Immunol. 2017 Nov 3;8:1366.
40. Zheng Y, Pollak J, Henderson K, **Hendrickson JE**, Tormey CA. A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia. Transfusion. 2018 Mar;58(3):775-780.
41. Gehrie EA, Roubinian NH, Chowdhury D, Brambilla DJ, Murphy EL, Gottschall JL, Wu Y, Ness PM, Strauss RG, **Hendrickson JE**; NHLBI Recipient Epidemiology-Donor Evaluation Study (REDS-III). A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions. Vox Sang. 2018 Feb;113(2):160-169.
42. Sullivan HC, Arthur CM, Thompson L, Patel SR, Stowell SR, **Hendrickson JE**, Lazarus AH. Anti-RhD reduces levels of detectable RhD antigen following anti-RhD infusion. Transfusion. 2018 Feb;58(2):542-544.
43. Roubinian NH, **Hendrickson JE**, Triulzi DJ, Gottschall JL, Michalkiewicz M, Chowdhury D, Kor DJ, Looney MR, Matthay MA, Kleinman SH, Brambilla D, Murphy EL; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Contemporary risk factors and outcomes of transfusion-associated circulatory overload. Crit Care Med. 2018 Apr;46(4):577-585.
44. Stahl M, Pine A, **Hendrickson JE**, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey(). Leuk Lymphoma. 2018 Apr 18:1-4.
45. Mener A, Arthur CM, Patel SR, Liu J, **Hendrickson JE**, Stowell SR. Complement component 3 negatively regulates antibody response by modulation of red blood cell antigen. Front Immunol. 2018 Jun 11;9:676.
46. Curtis G, Scott M, Orengo L, **Hendrickson JE**, Tormey CA. Very low rate of anti-D development in male, primarily immunocompetent patients transfused with D-mismatched platelets. Transfusion. 2018 Jun;58(6):1568-1569.
47. Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, **Hendrickson JE**; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol. 2018 Jun; 181(5): 672-681.
48. Curtis SA, Curtis BR, Lee AI, **Hendrickson JE**, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology. 2018 Aug;23(7):429-432.
49. Maier CL, Mener A, Patel SR, Jajosky RP, Bennett AL, Arthur CM, **Hendrickson JE**, Stowell SR. Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Adv. 2018 Nov 13;2(21):2986-3000.
50. Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, **Hendrickson JE**. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion. 2019 Jan;59(1):217-225.
51. Madrid DJ, Santhanakrishnan M, Liu J, Gibb DR, Liu D, Natarajan P, Beitler D, Shi Z, Mo C, Tormey CA, Patel SR, Stowell SR, **Hendrickson JE**. Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model. Blood Transfus. 2018 Nov 7:1-10.
52. Patel SR, Gibb DR, Girard-Pierce K, Zhou X, Rodrigues LC, Arthur CM, Bennett AL, Jajosky RP, Fuller M, Maier CL, Zerra PE, Chonat S, Smith NH, Tormey CA, **Hendrickson JE**, Stowell SR. Marginal zone B cells induce alloantibody formation following RBC transfusion. Front Immunol. 2018 Nov 16;9:2516.
53. Mener A, Patel SR, Arthur CM, Chonat S, Wieland A, Santhanakrishnan M, Liu J, Maier CL, Jajosky RP, Girard-Pierce K, Bennett A, Zerra PE, Smith NH, **Hendrickson JE**, Stowell SR. Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses. JCI Insight. 2018 Nov 15;3(22).
54. Baine I, Bahar B, **Hendrickson JE**, Hudson KE, Tormey CA. Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity. Transfusion. 2019 May;59(5):1651-1656.
55. Jones SA, Jones JM, Leung V, Nakashima AK, Oakeson KF, Smith AR, Hunter R, Kim JJ, Cumming M, McHale E, Young PP, Fridey JL, Kelley WE, Stramer SL, Wagner SJ, West FB, Herron R, Snyder E, **Hendrickson JE**, Peaper DR, Gundlapalli AV, Langelier C, Miller S, Nambiar A, Moayeri M, Kamm J, Moulton-Meissner H, Annambhotla P, Gable P, McAllister GA, Breaker E, Sula E, Halpin AL, Basavaraju SV. Sepsis attributed to bacterial contamination of platelets associated with a potential common source - Multiple States, 2018. MMWR Morb Mortal Wkly Rep. 2019 Jun 14;68(23):519-523.
56. Liu D, Gibb DR, Escamilla-Rivera V, Liu J, Santhanakrishnan M, Shi Z, Xu L, Eisenbarth SC, **Hendrickson JE**. Type 1 IFN signaling critically regulates influenza-induced alloimmunization to transfused KEL RBCs in a murine model. Transfusion. 2019 Oct;59(10):3243-3252.
57. MohanKumar K, Namachivayam K, Song T, Jake Cha B, Slate A, **Hendrickson JE**, Pan H, Wickline SA, Oh JY, Patel RP, He L, Torres BA, Maheshwari A. A murine neonatal model of necrotizing enterocolitis caused by anemia and red blood cell transfusions. Nat Commun. 2019 Aug 2;10(1):3494.
58. Balbuena-Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, **Hendrickson JE**. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion. 2019 Oct;59(10):3219-3227.
59. Sostin N, Ross R, Balbuena-Merle R, **Hendrickson JE**, Tormey CA. Passive anti-C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. J Clin Apher. 2020 Jun;35(3):224-226.
60. Nickel RS, Horan JT, Abraham A, Qayed M, Haight A, Ngwube A, Liang H, Luban NLC, **Hendrickson JE**. Human leukocyte antigen (HLA) class I antibodies and transfusion support in pediatric HLA-matched haematopoietic cell transplant for sickle cell disease. Br J Haematol. 2020 Apr;189(1):162-170.
61. Goshua G, Gokhale A, **Hendrickson JE**, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020 Feb 11;4(3):539-545.
62. Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena-Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, **Hendrickson JE**, Tormey CA; (for the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion. 2020 Apr;60(4):831-839.
63. Balbuena-Merle R, Santhanakrishnan M, Devine L, Gibb DR, Tormey CA, Siddon AJ, Curtis SA, Gallagher PG, Weinstein JS, **Hendrickson JE**. Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfus Apher Sci. 2020 Apr 27:102778.
64. Escamilla-Rivera V, Liu J, Gibb DR, Santhanakrishnan M, Liu D, Forsmo JE, Eisenbarth SC, Foxman EF, Stowell SR, Luckey CJ, Zimring JC, Hudson KE, **Hendrickson JE**. Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood. 2020 May 28;135(22):1983-1993.
65. Karafin MS, **Hendrickson JE**, Kim HC, Kuliya-Gwarzo A, Pagano MB, Perumbeti A, Shi PA, Tanhehco YC, Webb J, Wong E, Eichbaum Q. Red cell exchange for patients with sickle cell disease: an international survey of current practices. Transfusion. 2020 Jul;60(7):1424-1433.
66. Nickel, RS, Flegel, WA, Adams, SD, **Hendrickson, JE**, Liang, H, Tisdale, JF, Hsieh,MM. The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study. EClinicalMedicine. 2020;24:100432. Published 2020 Jun 28.
67. Gupta GK, **Hendrickson JE**, Tormey CA. Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura. J Clin Apher. 2020 Apr;35(2):140-141.
68. Curtis SA, Lew D, Spodick J, **Hendrickson JE**, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Adv. 2020;4(16):3814-3821.
69. Roubinian NH, Chowdhury D, **Hendrickson JE**, Triulzi DJ, Gottschall JL, Looney MR, Matthay MA, Kor DJ, Brambilla D, Kleinman SH, Murphy EL; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). NT-proBNP levels in the identification and classification of pulmonary transfusion reactions. Transfusion. 2020 Nov;60(11):2548-2556.
70. Gupta GK, **Hendrickson JE**, Bahel P, Siddon AJ, Rinder HM, Tormey CA. Factor V activity in apheresis platelets: Implications for management of FV deficiency. Transfusion. 2021 Feb;61(2):405-409.
71. O'Bryan J, Gokhale A, **Hendrickson JE**, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. J Clin Apher. 2021 Feb;36(1):127-134.
72. Goshua G, Sinha P, **Hendrickson JE**, Tormey CA, Bendapudi P, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021 Feb 18;137(7):969-976.
73. Gupta GK, Perreault S, Seropian SE, Tormey CA, **Hendrickson JE**. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfus Apher Sci. 2021 Jun;60(3):103069.
74. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, **Hendrickson JE**, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS One. 2021 Jul 28;16(7):e0254453.
75. Hanson SJ, Karam O, Birch R, Goel R, Patel RM, Sola-Visner M, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson CD, **Hendrickson JE**, Karafin MS, Nellis ME; NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Transfusion practices in pediatric cardiac surgery requiring cardiopulmonary bypass: A secondary analysis of a clinical database. Pediatr Crit Care Med. 2021 Nov 1;22(11):978-987.
76. Escamilla-Rivera V, Santhanakrishnan M, Liu J, Gibb DR, Forsmo JE, Foxman EF, Eisenbarth SC, Luckey CJ, Zimring JC, Hudson KE, Stowell SR, **Hendrickson JE**. Complement plays a critical role in inflammation-induced immunoprophylaxis failure in mice. Front Immunol. 2021 Jun 25;12:704072.
77. Medved J, Knott BM, Tarrah SN, Li AN, Shah N, Moscovich TC, Boscia AR, Salazar JE, Santhanakrishnan M, **Hendrickson JE**, Fu X, Zimring JC, Luckey CJ. The lysophospholipid-binding molecule CD1D is not required for the alloimmunization response to fresh or stored RBCs in mice despite RBC storage driving alterations in lysophospholipids. Transfusion. 2021 Jul;61(7):2169-2178.
78. Nellis ME, Goel R, **Hendrickson JE**, Birch R, Patel RM, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Sola-Visner M, Josephson CD, Karam O; NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Transfusion practices in a large cohort of hospitalized children. Transfusion. 2021 Jul;61(7):2042-2053.
79. Zerra PE, Patel SR, Jajosky RP, Arthur CM, McCoy JW, Allen JWL, Chonat S, Fasano RM, Roback JD, Josephson CD, **Hendrickson JE**, Stowell SR. Marginal zone B cells mediate a CD4 T-cell-dependent extrafollicular antibody response following RBC transfusion in mice. Blood. 2021 Aug 26;138(8):706-721.
80. Patel RM, **Hendrickson JE**, Nellis ME, Birch R, Goel R, Karam O, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Sola-Visner M; National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Variation in neonatal transfusion practice. J Pediatr. 2021 Aug;235:92-99.e4.
81. Madany E, Okwan-Duodu D, Balbuena-Merle R, **Hendrickson JE**, Gibb DR. Potential implications of a type 1 interferon gene signature on COVID-19 severity and chronic inflammation in sickle cell disease. Front Med (Lausanne). 2021 Jul 22;8:679030.
82. Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola-Visner MC, Hauser RG, Luban NLC, Gottschall J, Josephson CD, **Hendrickson JE**, Karafin MS; NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion. 2021 Sep;61(9):2589-2600.
83. Manrai PA, Siddon AJ, Hager KM, **Hendrickson JE**, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology. 2021 Sep;37(3):109-112.
84. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, **Hendrickson JE**. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A Randomized Clinical Trial. JAMA Intern Med. 2021 Dec 13:e216850.
85. Roubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, **Hendrickson JE**, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA. Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness. JCI Insight. 2021 Nov 18:e152598.
86. Curtis SA, Raisa BM, Roberts JD, **Hendrickson JE**, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfus Apher Sci. 2021 Oct 30:103304.
87. Soldatenko A, Hoyt LR, Xu L, Calabro S, Lewis SM, Gallman AE, Hudson KE, Stowell SR, Luckey CJ, Zimring JC, Liu D, Santhanakrishnan M, **Hendrickson JE**, Eisenbarth SC. Innate and adaptive immunity to transfused allogeneic RBCs in mice requires MyD88. J Immunol. 2022 Feb 15;208(4):991-997. doi: 10.4049/jimmunol.2100784. Epub 2022 Jan 17. PMID: 35039331.
88. Olsen GM, Tormey CA, Tseng B, **Hendrickson JE**, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. J Clin Apher. 2022 Feb;37(1):13-18.
89. Arthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, **Hendrickson JE**, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion. 2022 May;62(5):948-953.
90. Review Articles and Editorials:
91. Zimring JC and **Hendrickson JE**. The role of inflammation in alloimmunization to antigens on transfused RBCs. Current Opinion in Hematology 2008, 15(6):631-635.
92. **Hendrickson JE**, and Hillyer CD. Non-Infectious serious hazards of transfusion. Anesthesia and Analgesia 2009, 108(3): 759-769.
93. H. V. New, S. J. Stanworth, C. P. Engelfriet, H. W. Reesink, Z. K. McQuilten, H. F. Savoia, E. M. Wood, S. Olyntho, F. Trigo, S. Wendel, Y. Lin, H. Hume, J. Petäjä, T. Krusius, S. Villa, S. Ghirardello, J. von Lindern, A. Brand, **J. E. Hendrickson**, C. D. Josephson, R. G. Strauss, N. L. C. Luban & W. Paul. International forum: Neonatal transfusions. Vox Sanguinis 2009, 96: 62-85
94. Zimring JC, Stowell SR, Johnson J, and **Hendrickson JE**. The effect of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens; current paradigms and future considerations. Transfusion Clinique Biologique. 2012 Jun; 19(3): 125-31.
95. Stowell SR, Winker A, Maier C, Arthur M, Smith NH, Girard K, Cumming RD, Zimring JC, and **Hendrickson JE**. Initiation and regulation of complement during hemolytic transfusion reactions. Clinical and Developmental Immunology. 2012; 2012: 307093.
96. Tormey CA and **Hendrickson JE**. Antibodies of unknown significance: nuisance or near-miss? Transfusion. Transfusion. 2013 May; 53(5): 926-8.
97. **Hendrickson JE**, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfusion Medicine Reviews. 2014 July; 28(3): 137-144.
98. Ryder AB, Zimring JC, **Hendrickson JE**. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother. 2014 Nov; 41(6): 406-419.
99. **Hendrickson JE**, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev. 2014 Jul; 28(3): 137-44.
100. Siddon AJ, Rinder RM, **Hendrickson JE**, Tormey CA. Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage? Ann Hematol. 2015 August; 94(8): 1413-1414.
101. Tormey CA, **Hendrickson JE**. Routine non-ABO blood group antigen typing in sickle cell disease: the new frontier in pretransfusion testing? Transfusion 2015 Jun; 55(6 Pt 2): 1374-7.
102. **Hendrickson JE** and Delaney M. Hemolytic disease of the newborn: Modern practice and future investigations. Transfus Med Rev. 2016 Oct;30(4):159-64.
103. **Hendrickson JE**, Tormey CA. Transfusion medicine. Hematol Oncol Clin North Am. 2016 Jun;30(3):xiii-xiv.
104. **Hendrickson JE**, Tormey CA. Red blood cell antibodies in Hematology/Oncology patients: Interpretation of immunohematologic tests and clinical significance of detected antibodies. Hematol Oncol Clin North Am. 2016 Jun;30(3):635-651.
105. **Hendrickson JE**, Tormey CA. Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. Vaccine. 2016 Aug 31;34(38):4468.
106. **Hendrickson JE**, Eisenbarth SC, Tormey CA. Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Curr Opin Hematol. 2016 Nov;23(6):543-549.
107. Cheng CW, **Hendrickson JE**, Tormey CA, Sidhu D. Therapeutic plasma exchange and its impact on drug levels: An ACLPS Critical Review. Am J Clin Pathol. 2017 Sep 1;148(3):190-198.
108. Cheng C, Gokhale A, Tormey CA, **Hendrickson JE**, Bahar B. Preanalytical errors

in transfusion medicine: Reply to "74-year-old female with new monoclonal protein

on serum immunofixation electrophoresis". Clin Biochem. 2017

Dec;50(18):1334-1335.

1. Siddon AJ, Kenney BC, **Hendrickson JE**, Tormey CA. Delayed haemolytic and

serologic transfusion reactions: pathophysiology, treatment and prevention. Curr

Opin Hematol. 2018 Nov;25(6):459-467.

1. **Hendrickson JE**, Tormey CA. Rhesus pieces: genotype matching of RBCs. Blood. 2018 Sep 13;132(11):1091-1093.

.

1. Blitshteyn S, Brinth L, **Hendrickson JE**, Martinez-Lavin M. Autonomic

dysfunction and HPV immunization: an overview. Immunol Res. 2018

Dec;66(6):744-754.

1. **Hendrickson, JE**. Toll-like receptor SNPs and sickle cell disease: a PRRfect storm for RBC alloimmunization. Br J Haematol. 2019 Sep;186(6):803-804.
2. Balbuena-Merle R, **Hendrickson JE**. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Transfus Clin Biol. 2019 May;26(2):112-115.
3. Tormey CA, **Hendrickson JE**. Transfusion-related red blood cell alloantibodies:

induction and consequences. Blood. 2019 Apr 25;133(17):1821-1830.

1. Hauser RG, **Hendrickson JE**, Tormey CA. TRIX with treats: the considerable

safety benefits of a transfusion medicine registry. Transfusion. 2019

Aug;59(8):2489-2492.

1. Hudson KE, Fasano RM, Karafin MS, **Hendrickson JE**, Francis RO. Mechanisms of alloimmunization in sickle cell disease. Curr Opin Hematol. 2019

Nov;26(6):434-441.

1. Ní Loingsigh S, Flegel WA, **Hendrickson JE**, Tormey CA. Preventing transfusion-associated graft-versus-host disease with blood component irradiation: indispensable guidance for a deadly disorder Br J Haematol. 2020 Dec;191(5):653-657.
2. Shallis RM, Stahl M, Bewersdorf JP, **Hendrickson JE**, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020;13(5):489-499.
3. **Hendrickson JE**, Mendoza H, Ross R, Siddon AJ, Gowda L, Hauser RG, Schulz WL, Tormey CA. Investigation of increased platelet alloimmunization screening in the era of pathogen-reduced platelets treated with psoralen/UV light. Transfusion. 2020 Mar;60(3):650-651.
4. Thein SL, Pirenne F, Fasano RM, Habibi A, Bartolucci P, Chonat S, **Hendrickson JE**, Stowell SR. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica. 2020 Mar;105(3):539-544.
5. **Hendrickson JE**, Tormey CA. COVID-19 and the Coombs test. Blood. 2020;136(6):655-656.
6. Gupta GK, Balbuena-Merle R, **Hendrickson JE**, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfus Apher Sci. 2020 Sep 16:102946.
7. Sostin N, **Hendrickson JE**. Pediatric hemovigilance and adverse transfusion reactions. Clin Lab Med. 2021 Mar;41(1):51-67.
8. **Hendrickson JE**. Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Ann Blood. 2020 Dec;5:33.
9. Lee ES, **Hendrickson JE**, Tormey CA. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary? Transfusion. 2021 Dec;61(12):3283-3285.

1. Symposium Contributions:
2. **Hendrickson JE**. Red blood cell alloimmunization: of mice, men, and women. European Hematology Association Education Book, 2011*.*
3. **Hendrickson JE** and Tormey CA. Acute hemolysis in a 3 yo child. ASCP CME Series: Lab-Q. 2013.
4. **Hendrickson JE** and Tormey CA. Allo or auto Anti-C? A laboratory and clinical dilemma. ASCP CME Series: Lab-Q. 2013
5. **Hendrickson JE** and multiple other authors (lead authors Paidas MJ and Kupfer G). Personalizing the management of hemophilia: Hemophilia Journal Supplement and CME Series for the France Foundation. 2014.
6. **Hendrickson JE,** Tormey CA. Understanding red blood cell alloimmunization

triggers. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):446-451.

1. **Hendrickson, JE**. Red blood cell alloimmunization: induction of immunity and potential mitigation strategies. ISBT Science Series, 2017.
2. **Hendrickson, JE.** Recipient factors influencing red blood cell alloimmunization. ISBT Science Series, 2019.
3. **Hendrickson JE**, Fasano RM. Management of hemolytic transfusion reactions.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):704-709.
4. Book Chapters:
5. **Hendrickson JE** and Roback JD. Transfusion of the HIV Positive Patient. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
6. **Hendrickson JE** and Roback JD. Transfusion of Patients Refractory to Platelet Transfusions. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
7. **Hendrickson JE** and Roback JD. Transfusion Management in Patients Who Refuse Blood Transfusion. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
8. **Hendrickson JE** and Roback JD. Transfusion of Patients Undergoing HPC and Solid Organ Transplantation. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
9. Darrow M, **Hendrickson JE**, and Roback JD. Extracorporeal Photopheresis. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
10. **Hendrickson JE**, and Josephson CD. Neonatal and Pediatric Transfusion Medicine. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
11. **Hendrickson JE**, and Hillyer CD. Transfusion-Associated Circulatory Overload. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
12. **Hendrickson JE**, and Hillyer CD. Transfusion-Related Acute Lung Injury. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects. Elsevier, 2009.
13. Miller BE, and **Hendrickson JE**. Chapter 11: Coagulation, Bleeding, and Blood Transfusion. Gregory’s Pediatric Anesthesia, Fifth Edition, pages 224-254. GA Gregory and DB Andropoulos, Editors. Wiley Blackwell, 2012.

1. **Hendrickson JE**. Transfusion of Patients Refractory to Platelet Transfusions. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
2. **Hendrickson JE**. Transfusion Management in Patients Who Refuse Blood Transfusion. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
3. **Hendrickson JE**. Transfusion of Patients Undergoing HPC and Solid Organ Transplantation. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
4. **Hendrickson JE**, and Josephson CD. Neonatal and Pediatric Transfusion Medicine. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
5. **Hendrickson JE**, and Hillyer CD. Transfusion-Associated Circulatory Overload. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
6. **Hendrickson JE**, and Hillyer CD. Transfusion-Related Acute Lung Injury. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 2nd Edition. Elsevier, 2013.
7. **Hendrickson JE** and Tormey CA. Transfusion Support for Hematopoietic Stem Cell Transplant Recipients. AABB Technical Manual, written in 2013.
8. **Hendrickson JE** and Tormey CA. The RBC as a Target of Damage. Pathobiology of Human Disease. Elsevier, 2014.
9. Fasano RM, **Hendrickson JE**, Luban NLC. Alloimmune Hemolytic Disease of the Fetus and Newborn. Chapter 55 in Williams Hematology, 9th edition. Editors: Kaushansky, Lichtman,Kipps, Prchal, Levi, Burns, Press. McGraw-Hill. 2015.
10. **Hendrickson JE** and Josephson CD. Platelet and Plasma Transfusion for Infants and Children. Chapter 47 in Rossi’s Principles of Transfusion Medicine, 5th edition. Editors: Simon, McCullough, Snyder, Solheim, Strauss. Wiley. 2015.
11. Cushing MM and **Hendrickson JE**. Transfusion Support for Hematopoietic Stem Cell Transplant Recipients. AABB Technical Manual, 2017.
12. Tormey CA, Gehrie EA, **Hendrickson JE**. Data interpretation. Chapter 21 in Transfusion Medicine, Apheresis, and Hemostasis, 1st edition. Elsevier, 2017. **Hendrickson JE** and Fasano RM. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. Sickle Cell Disease and Hematopoietic Stem Cell Transplantation, 1st edition. Editors: Emily Riehm Meier, Allistair Abraham, and Ross Fasano. Springer, 2018.
13. Baine IL, **Hendrickson JE**, Tormey CA. Common Significant non-ABO Antibodies and Blood Group Antigen Alloimmunization. Clinical Principles of Transfusion Medicine, 1st edition. Editor: Robert Maitta. Elsevier, 2018.
14. Tormey CA and **Hendrickson JE**. Transfusion of Patients Refractory to Platelet Transfusions. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
15. Bahar B and **Hendrickson JE**. Transfusion Management in Patients Who Refuse Blood Transfusion. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
16. Rutter S and **Hendrickson JE**. Transfusion of Patients Undergoing HPC and Solid Organ Transplantation. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
17. Zerra P and **Hendrickson JE**, and Josephson CD. Neonatal and Pediatric Transfusion Medicine. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
18. Gokhale A and **Hendrickson JE**. Transfusion-Associated Circulatory Overload. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
19. Gokhale A and **Hendrickson JE**. Transfusion-Related Acute Lung Injury. Transfusion Medicine and Coagulation: Clinical and Laboratory Aspects, 3rd Edition. Elsevier, 2018.
20. Fasano RM, **Hendrickson JE**, Luban NLC. Alloimmune Hemolytic Disease of the Fetus and Newborn. Chapter 56 in Williams Hematology, 10th edition. Editors: Kaushansky, Lichtman, Prchal, Levi, Burns, Linch. McGraw-Hill. 2021.
21. **Hendrickson JE** and Josephson CD. Transfusion in Infants and Children. Chapter 32 in Rossi’s Principles of Transfusion Medicine, 6th edition. 2021.
22. L. Lieberman **and Hendrickson JE**. Consent and an Approach to Management of Acute and Chronic Adverse Events. Chapter 7 in Hemostasis Management for the Pediatric Surgical Patient. 2022, in press.
23. Published Abstracts: Please refer to section 26 above; all abstracts presented at the AABB and ASH Annual Meetings are published annually in a special edition of Transfusion and Blood, respectively.
24. Other Publications (including case reports and practice guidelines)
25. Adisa O, **Hendrickson JE**, Hopkins CK, Katzenstein HM, Josephson CD. Polycythemia in an infant secondary to granulocyte transfusions. Pediatric Blood and Cancer, 2011 Dec 15; 57(7): 1236-8.
26. **Hendrickson JE**, Hendrickson ET, Gehrie EA, Sidhu D, Wallukat G, Schimke I, Tormey CA. Complex regional pain syndrome and dysautonomia in a 14-year old girl responsive to therapeutic plasma exchange. J. Clin Apheresis. 2016 Aug;31(4):368-74.
27. Balbuena-Merle R, West FB, Tormey CA, **Hendrickson JE**. Fatal acute hemolytic transfusion reaction due to anti-B from a platelet apheresis unit stored in platelet additive solution. Transfusion. 2019 Jun;59(6): 1911-1915.
28. Chou ST, Alsawas M, Fasano RM, Field JJ, **Hendrickson JE**, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020 Jan 28;4(2):327-355.
29. Jacobs JW, Guarente J, **Hendrickson JE**, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. J Clin Apher. 2021 Dec 25. doi: 10.1002/jca.21962. Epub ahead of print. PMID: 34953078.
30. Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, **Hendrickson JE**, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz-Diaz E, Nahirniak S, New HV, Pavenski K, Dos Santos MCP, Ramsey G, Shehata N; International Collaboration for Transfusion Medicine Guidelines (ICTMG). International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn. Br J Haematol. 2022 Apr 12. doi: 10.1111/bjh.18170. Epub ahead of print. PMID: 35415922.